Page last updated: 2024-11-05

pyrazolanthrone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pyrazolanthrone is a heterocyclic compound with a unique structure that consists of a fused pyrazole and anthrone ring system. It has been extensively studied for its potential applications in various fields, including organic electronics, dye chemistry, and materials science.

The synthesis of pyrazolanthrone typically involves condensation reactions of aniline derivatives with 1,3-dicarbonyl compounds. The resulting compound can be further modified through various functionalization reactions, such as halogenation, alkylation, and acylation.

Pyrazolanthrone derivatives exhibit interesting electronic and optical properties, such as strong fluorescence and good electron-transporting capabilities. These properties make them promising candidates for use in organic light-emitting diodes (OLEDs), organic solar cells, and other optoelectronic devices.

Furthermore, pyrazolanthrones have been explored as dyes due to their ability to absorb light in the visible region. They have also shown potential as chemosensors for the detection of metal ions and other analytes.

The research on pyrazolanthrone is driven by the desire to develop novel materials with enhanced properties and applications. Its unique structure and diverse functionalities make it a valuable compound for exploring new frontiers in organic chemistry and materials science.'
```

pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8515
CHEMBL ID7064
CHEMBL ID1725279
CHEBI ID90695
SCHEMBL ID170980
SCHEMBL ID15583517
MeSH IDM0395046

Synonyms (163)

Synonym
CBIOL_002049
einecs 204-955-6
brn 0746890
nsc 75890
MLS002153267
smr000015440
HY-12041
HMS3267P06
BRD-K01567962-001-06-5
BRD-K01567962-001-04-0
2h-dibenzo[cd,g]indazol-6-one
anthra-1,9-pyrazol-6-none
sp 600125 & z-100
anthra[1,9-cd]pyrazol-6(2h)-one & z-100
EU-0100473
sp600125, >=98% (hplc)
BIOMOLKI_000068
K00068
tocris-1496
BIO1_001313
BIO1_000335
lopac-s-5567
NCGC00025186-01
BIO2_000853
NCGC00015958-01
BIO2_000373
BIO1_000824
BIOMOLKI2_000072
IDI1_002128
2h-dibenzo(cd,g)indazol-6-one
129-56-6
wln: t c6665 1a p iv omnj
c.i. 70300
nsc75890
pyrazoleanthrone
mls002693964 ,
anthra[1,9-cd]pyrazol-6(2h)-one
1,9-pyrazoloanthrone ,
pyrazolanthrone
nsc-75890
SMP2_000240
LOPAC0_000473
HSCI1_000136
BSPBIO_001066
BCBCMAP01_000053
QTL1_000077
sp 600125
chembiol10705 compound 4
jmc517015 compound 2
cid_8515
sp-600125
dibenzo[cd,g]indazol-6(2h)-one
1PMV ,
bdbm16018
chembl7064 ,
DB01782
14,15-diazatetracyclo[7.6.1.0;{2,7}.0;{13,16}]hexadeca-1(15),2(7),3,5,9(16),10,12-heptaen-8-one
anthra(1,9-cd)pyrazol-6(2h)-one
jnk inhibitor ii
NCGC00025186-04
NCGC00025186-05
sp600125 ,
KBIOSS_000406
KBIO3_000772
KBIO2_002974
KBIOGR_000406
KBIO2_000406
KBIO2_005542
KBIO3_000771
SR-01000637108-1
NCGC00025186-02
NCGC00025186-03
NCGC00015958-03
HMS1990F07
S 5567
anthrapyrazolone; 1,9-pyrazoloanthrone
NCGC00015958-08
AKOS000115584
HMS1667K13
BMK1-G8
HMS1362F07
HMS1792F07
HMS3229I16
chebi:90695 ,
KINOME_3844
HMS3261O08
14,15-diazatetracyclo[7.6.1.0^{2,7}.0^{13,16}]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one
EN300-02083
cas-129-56-6
dtxcid0020525
dtxsid2040525 ,
tox21_110267
HMS2250C03
CCG-100672
CCG-47500
NCGC00015958-07
NCGC00015958-04
NCGC00015958-02
NCGC00015958-06
NCGC00015958-05
CS-0196
unii-1tw30y2766
1tw30y2766 ,
F1414-1245
FT-0607068
LP00473
bdbm50433916
2ZMD
S1460
S10332
CHEMBL1725279
gtpl5273
AB00075935-01
2,6-dihydrodibenzo[cd,g]indazol-6-one
anthra[1,9cd]pyrazol-6(2h)-one
MLS006011577
smr002530644
SCHEMBL170980
NCGC00261158-01
tox21_500473
SCHEMBL15583517
anthra[1-9-cd]pyrazol-6(2h)-one
dibenzo[cd,g]indazol-6(2h)-one #
HB2234
W-108360
HMS3403F07
SR-01000075840-6
sr-01000075840
ci 70300
bdbm50024294
mfcd00022289
HMS3654P10
14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one
AC-32051
Z56785477
SR-01000075840-2
SR-01000075840-4
SR-01000075840-1
SW218106-2
1,6-dihydrodibenzo[cd,g]indazol-6-one
BCP05457
Q4545713
jnk inhibitor ii - cas 129-56-6
HMS3676F05
anthra[1,9-cd]pyrazol-6-one
AS-14374
HMS3412F05
BRD-K01567962-001-08-1
BRD-K01567962-001-22-2
SDCCGSBI-0050458.P003
HMS3295M01
NCGC00015958-22
AMY31086
HMS3747M19
EX-A1998
anthra[1,9-cd]pyrazol-6(2h)-one;sp-600125
A888840
nsc-755773
nsc755773
pyrazolanthrone (sp600125)
wln: t c66651a p iv omnj
AKOS040751313
SY052909

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Mouse hepatocytes and C57BL/6 mice were administered a toxic dose of APAP with or without SP600125, a chemical c-jun N-terminal kinase (JNK) inhibitor."( c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity.
Gaarde, WA; Gunawan, BK; Han, D; Hanawa, N; Kaplowitz, N; Liu, ZX, 2006
)
0.33
" We investigated the hypotheses that these drugs (A) are less neurotoxic than the prototype local anesthetic, lidocaine (B) are selectively toxic for subcategories of dorsal root ganglion neurons and (C) induce activation of either p38 MAPK or related enzymes, such as the c-jun terminal N-kinase (JNK) and extracellular signal-regulated kinase (ERK)."( In vitro, inhibition of mitogen-activated protein kinase pathways protects against bupivacaine- and ropivacaine-induced neurotoxicity.
Colvin, HP; Gerner, P; Haller, I; Klimaschewski, L; Lang, L; Lirk, P; Tomaselli, B, 2008
)
0.35
" In conclusion, deferoxamine is directly toxic on RPE cells, its toxicity depending on p38."( Deferoxamine mesylate is toxic for retinal pigment epithelium cells in vitro, and its toxicity is mediated by p38.
Herdegen, T; Klettner, A; Koinzer, S; Roider, J; Waetzig, V, 2010
)
0.36
"Combined curcumin and PS-341 treatment has been reported to enhance cytotoxicity and minimize adverse effects through ERK and p38MAPK mechanisms in human multiple myeloma cells."( Curcumin enhances cytotoxic effects of bortezomib in human multiple myeloma H929 cells: potential roles of NF-κB/JNK.
Bai, QX; Zhang, XY, 2012
)
0.38
" The NCP-cultured HepG2 cells showed higher expression of mRNA and protein levels of cytochrome P450 2E1, which metabolizes APAP to a toxic metabolite, APAP-cysteine adduct formation, and higher sensitivity against APAP-induced cell injury compared with conventionally cultured cells."( Evaluation of three-dimensional cultured HepG2 cells in a nano culture plate system: an in vitro human model of acetaminophen hepatotoxicity.
Abe, N; Aritomi, K; Irie, T; Irikura, M; Ishitsuka, Y; Kai, H; Shimizu, D; Shuto, T; Tomishima, Y, 2014
)
0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
" With intratumoral injections of TRAIL combined with hyperthermia at 42 degrees C, we were able to show a delayed onset of tumor growth in our xenograft model."( Effect of hyperthermia in combination with TRAIL on the JNK-Bim signal transduction pathway and growth of xenograft tumors.
Alcala, MA; Bartlett, DL; Lee, BC; Lee, DH; Lee, YJ; Park, BH; Park, K; Yoo, J, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The aim of this study was to improve tumor-specific delivery and bioavailability of a nanoparticle-mediated radiosensitizer in mouse brain tumor models."( Enhancing Radiotherapeutic Effect With Nanoparticle-Mediated Radiosensitizer Delivery Guided By Focused Gamma Rays In Lewis Lung Carcinoma-Bearing Mouse Brain Tumor Models.
Choi, JM; Jang, WY; Jeong, YI; Jung, S; Li, CH; Lim, SH, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" We show that at therapeutic dosage (or at micromolar range), flavopiridol almost completely prevents colchicine-induced apoptosis in cerebellar granule neurones."( Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis.
Bravo, R; Bruna, A; Caelles, C; Camarasa, J; Camins, A; Canudas, AM; Escubedo, E; Jiménez, A; Jorda, EG; Pallàs, M; Pubill, D; Verdaguer, E, 2003
)
0.32
" The cells were pretreated with various doses of MTX including therapeutic dosage for RA, and then stimulated by PGD2."( Methotrexate enhances prostaglandin D2-stimulated heat shock protein 27 induction in osteoblasts.
Hirade, K; Ishisaki, A; Ito, H; Kato, K; Kozawa, O; Niwa, M; Shimizu, K; Yoshida, M, 2004
)
0.32
"Hormesis, a biphasic dose-response phenomenon, is characterized by a low-dose stimulation and a high-dose inhibition."( Biphasic effect of cadmium on cell proliferation in human embryo lung fibroblast cells and its molecular mechanism.
Duan, W; Jiang, G; Song, S; Wu, L; Xu, L; Zhu, C, 2009
)
0.35
" Cumulative dexmedetomidine (10⁻⁹ to 10⁻⁶ M) dose-response curves were generated in the presence or absence of extracellular signal-regulated kinase (ERK) inhibitor PD 98059, p38 MAPK inhibitor SB 203580, c-Jun NH₂-terminal kinase (JNK) inhibitor SP 600125, L-type calcium channel blocker (verapamil and nifedipine), and α₂-adrenoceptor inhibitor atipamezole."( c-Jun NH₂-terminal kinase contributes to dexmedetomidine-induced contraction in isolated rat aortic smooth muscle.
Chang, KC; Jeong, YS; Kim, HJ; Kim, JG; Kwon, SC; Lee, SM; Ok, SH; Sohn, JT; Sung, HJ, 2011
)
0.37
" Dose-response analyses were performed for various AhR ligands, including TCDD, 3-methylcholanthrene, indirubin, resveratrol, omeprazole, and SP600125."( Novel stably transfected gene reporter human hepatoma cell line for assessment of aryl hydrocarbon receptor transcriptional activity: construction and characterization.
Dvorak, Z; Novotna, A; Pavek, P, 2011
)
0.37
" SP600125 (a c-Jun NH2-terminal kinase [JNK] inhibitor) dose-response curves were generated in aortas that were pre-contracted with DMT or phorbol 12,13-dibutyrate (PDBu), a protein kinase C (PKC) activator."( Dexmedetomidine-induced contraction involves phosphorylation of caldesmon by JNK in endothelium-denuded rat aortas.
Baik, J; Cho, H; Choi, MJ; Kim, W; Lee, HK; Nam, IK; Ok, SH; Sohn, JT; Yu, J, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
c-Jun N-terminal kinase inhibitorAn EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor that inhibits the action of c-Jun N-terminal kinase.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
anthrapyrazoleAny organic heterotetracyclic compound consisting of a pyrazole ring ortho-fused to an anthracene.
cyclic ketone
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (134)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency25.78390.003245.467312,589.2998AID1705; AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency12.58930.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency17.78285.623417.292931.6228AID2323
LuciferasePhotinus pyralis (common eastern firefly)Potency28.69540.007215.758889.3584AID624030
acid sphingomyelinaseHomo sapiens (human)Potency25.118914.125424.061339.8107AID504937
endonuclease IVEscherichia coliPotency3.98110.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency38.44950.100020.879379.4328AID588453; AID588456
RGS12Homo sapiens (human)Potency25.11890.794310.991425.1189AID879
GLS proteinHomo sapiens (human)Potency6.30960.35487.935539.8107AID624146
PPM1D proteinHomo sapiens (human)Potency16.53880.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency18.71730.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency11.22020.180013.557439.8107AID1460
ThrombopoietinHomo sapiens (human)Potency5.01190.02517.304831.6228AID917; AID918
AR proteinHomo sapiens (human)Potency22.91420.000221.22318,912.5098AID743035; AID743036
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency15.20580.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency15.84890.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
regulator of G-protein signaling 4Homo sapiens (human)Potency37.68580.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency17.77240.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency23.71010.001530.607315,848.9004AID1224819; AID1224820
estrogen nuclear receptor alphaHomo sapiens (human)Potency14.20730.000229.305416,493.5996AID743069; AID743075; AID743078; AID743080; AID743091
67.9K proteinVaccinia virusPotency33.72710.00018.4406100.0000AID720579
ParkinHomo sapiens (human)Potency19.47630.819914.830644.6684AID720572; AID720573
arylsulfatase AHomo sapiens (human)Potency0.60121.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency6.57580.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency29.84930.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency3.75780.001723.839378.1014AID743083
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency0.39810.00207.533739.8107AID891
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency10.32250.01262.451825.0177AID485313
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
cytochrome P450 2C9 precursorHomo sapiens (human)Potency28.37090.00636.904339.8107AID883
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency8.49210.134610.395030.1313AID1347049
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency50.11870.354828.065989.1251AID504847
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency11.88320.000323.4451159.6830AID743065; AID743067
guanine nucleotide-binding protein G(i) subunit alpha-1 isoform 1Homo sapiens (human)Potency25.11890.794312.126325.1189AID879
importin subunit beta-1 isoform 1Homo sapiens (human)Potency35.48135.804836.130665.1308AID540253
DNA polymerase betaHomo sapiens (human)Potency31.62280.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency10.00000.039816.784239.8107AID995
flap endonuclease 1Homo sapiens (human)Potency11.47310.133725.412989.1251AID588795
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency20.74910.00378.618923.2809AID2668
snurportin-1Homo sapiens (human)Potency35.48135.804836.130665.1308AID540253
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency31.62280.010323.856763.0957AID2662
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency24.62080.425612.059128.1838AID504536; AID504891
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency35.48135.804816.996225.9290AID540253
DNA polymerase eta isoform 1Homo sapiens (human)Potency22.38720.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency28.18380.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency22.05270.15855.287912.5893AID493164; AID540303
plasminogen precursorMus musculus (house mouse)Potency22.05270.15855.287912.5893AID493164; AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency22.05270.15855.287912.5893AID493164; AID540303
gemininHomo sapiens (human)Potency32.88510.004611.374133.4983AID493164
DNA polymerase kappa isoform 1Homo sapiens (human)Potency10.00000.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency3.98110.031610.279239.8107AID884; AID885
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency10.00000.00419.962528.1838AID2675
caspase-1 isoform alpha precursorHomo sapiens (human)Potency3.98110.000311.448431.6228AID900
lethal factor (plasmid)Bacillus anthracis str. A2012Potency15.84890.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.00500.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency16.53880.00339.158239.8107AID1347411
Cellular tumor antigen p53Homo sapiens (human)Potency14.09620.002319.595674.0614AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency28.37090.00638.235039.8107AID883
Caspase-7Homo sapiens (human)Potency3.16233.981118.585631.6228AID889
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Guanine nucleotide-binding protein GHomo sapiens (human)Potency50.11871.995325.532750.1187AID624287
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
TAR DNA-binding protein 43Homo sapiens (human)Potency6.30961.778316.208135.4813AID652104
GABA theta subunitRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Single-stranded DNA cytosine deaminaseHomo sapiens (human)Potency79.432828.183860.145389.1251AID1347430
2,3-bisphosphoglycerate-independent phosphoglycerate mutaseLeishmania major strain FriedlinPotency21.33137.568615.230621.3313AID504548
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency42.56150.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Mitogen-activated protein kinase 10Homo sapiens (human)IC50 (µMol)0.15000.15000.15000.1500AID977608
Chain A, Mitogen-activated protein kinase 10Homo sapiens (human)IC50 (µMol)0.15000.15000.15000.1500AID977608
Chain A, Mitogen-activated protein kinase 10Homo sapiens (human)IC50 (µMol)0.15000.15000.15000.1500AID977608
TPA: protein transporter TIM10Saccharomyces cerevisiae S288CIC50 (µMol)73.40000.580026.547675.8000AID504657; AID504672
TPA: protein transporter TIM23Saccharomyces cerevisiae S288CIC50 (µMol)6.31000.880010.503632.9000AID493002
polyadenylate-binding protein 1Homo sapiens (human)IC50 (µMol)48.42504.910023.702976.1900AID602259; AID602260
Serine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)IC50 (µMol)0.72000.04532.28609.9390AID1801919
ReninHomo sapiens (human)IC50 (µMol)50.00000.00000.77968.2000AID617672
Interferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)IC50 (µMol)8.00000.10002.67828.0000AID606664
Dual specificity protein kinase TTKHomo sapiens (human)IC50 (µMol)0.89870.00180.33662.5000AID1184501; AID1552053; AID747744
Mitogen-activated protein kinase 8Homo sapiens (human)IC50 (µMol)6.10080.00201.01735.4200AID1189540; AID1530272; AID1530274; AID1799705; AID1876279; AID1889884; AID319311; AID325696; AID473195; AID617672; AID617673
Mitogen-activated protein kinase 9Homo sapiens (human)IC50 (µMol)1.01110.00500.74755.2000AID1189541; AID1530272; AID1530274; AID1799705; AID1876279; AID1889887; AID325697; AID473196
Tyrosine-protein kinase JAK3Homo sapiens (human)IC50 (µMol)0.95700.00010.41937.9200AID1798646; AID389516
Mitogen-activated protein kinase 10Homo sapiens (human)IC50 (µMol)3.32470.00201.703510.0000AID1189542; AID1530272; AID1530274; AID1739951; AID1797457; AID1799705; AID1861945; AID1876280; AID1889885; AID311015; AID325698; AID473197; AID740242
Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)15.07500.00010.72667.8000AID1797457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Serine/threonine-protein kinase PLK4Homo sapiens (human)Kd0.77000.00081.51449.0000AID256607
Aurora kinase AHomo sapiens (human)Kd0.98000.00010.73429.3000AID256613
Cyclin-G-associated kinaseHomo sapiens (human)Kd0.03800.00030.908628.6510AID256612
3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)Kd1.25000.00171.34323.5000AID1802072
Death-associated protein kinase 3Homo sapiens (human)Kd0.41000.00101.82419.9000AID256659
Ribosomal protein S6 kinase alpha-5Homo sapiens (human)Kd1.70000.01701.973729.9570AID256648
Serine/threonine-protein kinase 16Homo sapiens (human)Kd0.51000.00171.24839.9690AID256606
Phosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)Kd0.48000.00012.05699.5000AID256618
Cyclin-dependent kinase 2Homo sapiens (human)Kd3.20000.00701.517910.4870AID256632
Ephrin type-A receptor 3Homo sapiens (human)Kd4.00000.00012.15218.6000AID256601
Dual specificity protein kinase TTKHomo sapiens (human)Kd0.09800.00651.62698.5000AID256599
Mitogen-activated protein kinase 8Homo sapiens (human)Kd0.10000.01102.096526.0590AID1530258; AID256622
Mitogen-activated protein kinase 9Homo sapiens (human)Kd0.08400.00201.45968.1000AID1530259; AID256637
Casein kinase I isoform epsilonHomo sapiens (human)Kd3.10000.01301.408612.4090AID256644
Dual specificity protein kinase CLK2Homo sapiens (human)Kd0.30000.00701.13846.5000AID256596
Mitogen-activated protein kinase 12Homo sapiens (human)Kd2.40000.00012.21389.9000AID256615
Mitogen-activated protein kinase 10Homo sapiens (human)Kd0.02200.00101.63545.9000AID1530260; AID256636
Cyclin-dependent kinase 16Homo sapiens (human)Kd0.18000.00111.585510.0000AID256588
Serine/threonine-protein kinase 4Homo sapiens (human)Kd2.20000.00021.712025.9020AID256586
Calcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)Kd4.10000.02702.29257.0000AID256643
Ribosomal protein S6 kinase alpha-2Homo sapiens (human)Kd2.20000.00892.04219.6000AID256627
AP2-associated protein kinase 1Homo sapiens (human)Kd0.03500.00121.370713.7110AID256609
Serine/threonine-protein kinase ULK3Mus musculus (house mouse)Kd0.68000.00301.10383.8000AID256563
Serine/threonine-protein kinase MARK2Homo sapiens (human)Kd1.80000.00011.842511.1030AID256608
Calcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)Kd1.40000.00111.85475.9000AID256584
Calcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)Kd4.20000.00101.91486.8000AID256581
Calcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)Kd7.50000.00003.233152.8470AID256580
STE20-like serine/threonine-protein kinase Homo sapiens (human)Kd2.30000.00003.857399.2320AID256578
Dual specificity protein kinase CLK4Homo sapiens (human)Kd0.26000.00201.41228.3000AID256577
MAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)Kd1.00000.00141.41315.7000AID256576
Casein kinase I isoform gamma-1Homo sapiens (human)Kd3.70000.05302.06225.7000AID256655
Serine/threonine-protein kinase 3Mus musculus (house mouse)Kd0.22000.00020.31401.1000AID256574
BMP-2-inducible protein kinaseHomo sapiens (human)Kd0.02500.00222.409756.0320AID256571
Serine/threonine-protein kinase pim-2Homo sapiens (human)Kd0.46000.00190.84155.0000AID256570
Serine/threonine-protein kinase 17AHomo sapiens (human)Kd2.10000.00101.72189.0000AID256568
Death-associated protein kinase 2Homo sapiens (human)Kd0.61000.00161.12619.1000AID256651
TRAF2 and NCK-interacting protein kinaseHomo sapiens (human)Kd0.48000.00471.393510.0000AID256566
Aurora kinase CHomo sapiens (human)Kd5.30000.00131.08488.7000AID256610
Serine/threonine-protein kinase 38-likeHomo sapiens (human)Kd2.30000.02801.46926.9000AID256677
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (583)

Processvia Protein(s)Taxonomy
positive regulation of centriole replicationSerine/threonine-protein kinase PLK4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PLK4Homo sapiens (human)
centriole replicationSerine/threonine-protein kinase PLK4Homo sapiens (human)
positive regulation of centriole replicationSerine/threonine-protein kinase PLK4Homo sapiens (human)
cilium assemblySerine/threonine-protein kinase PLK4Homo sapiens (human)
trophoblast giant cell differentiationSerine/threonine-protein kinase PLK4Homo sapiens (human)
de novo centriole assembly involved in multi-ciliated epithelial cell differentiationSerine/threonine-protein kinase PLK4Homo sapiens (human)
protein phosphorylationAurora kinase AHomo sapiens (human)
response to woundingAurora kinase AHomo sapiens (human)
liver regenerationAurora kinase AHomo sapiens (human)
G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
mitotic cell cycleAurora kinase AHomo sapiens (human)
chromatin remodelingAurora kinase AHomo sapiens (human)
protein phosphorylationAurora kinase AHomo sapiens (human)
apoptotic processAurora kinase AHomo sapiens (human)
spindle organizationAurora kinase AHomo sapiens (human)
spindle assembly involved in female meiosis IAurora kinase AHomo sapiens (human)
mitotic centrosome separationAurora kinase AHomo sapiens (human)
anterior/posterior axis specificationAurora kinase AHomo sapiens (human)
regulation of G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
negative regulation of gene expressionAurora kinase AHomo sapiens (human)
peptidyl-serine phosphorylationAurora kinase AHomo sapiens (human)
regulation of protein stabilityAurora kinase AHomo sapiens (human)
negative regulation of protein bindingAurora kinase AHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
negative regulation of apoptotic processAurora kinase AHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
positive regulation of mitotic nuclear divisionAurora kinase AHomo sapiens (human)
positive regulation of mitotic cell cycleAurora kinase AHomo sapiens (human)
regulation of centrosome cycleAurora kinase AHomo sapiens (human)
protein autophosphorylationAurora kinase AHomo sapiens (human)
cell divisionAurora kinase AHomo sapiens (human)
centrosome localizationAurora kinase AHomo sapiens (human)
cilium disassemblyAurora kinase AHomo sapiens (human)
protein localization to centrosomeAurora kinase AHomo sapiens (human)
positive regulation of mitochondrial fissionAurora kinase AHomo sapiens (human)
positive regulation of oocyte maturationAurora kinase AHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase AHomo sapiens (human)
neuron projection extensionAurora kinase AHomo sapiens (human)
mitotic spindle organizationAurora kinase AHomo sapiens (human)
regulation of cytokinesisAurora kinase AHomo sapiens (human)
receptor-mediated endocytosisCyclin-G-associated kinaseHomo sapiens (human)
endoplasmic reticulum organizationCyclin-G-associated kinaseHomo sapiens (human)
Golgi organizationCyclin-G-associated kinaseHomo sapiens (human)
negative regulation of neuron projection developmentCyclin-G-associated kinaseHomo sapiens (human)
synaptic vesicle uncoatingCyclin-G-associated kinaseHomo sapiens (human)
protein localization to Golgi apparatusCyclin-G-associated kinaseHomo sapiens (human)
intracellular transportCyclin-G-associated kinaseHomo sapiens (human)
clathrin coat assemblyCyclin-G-associated kinaseHomo sapiens (human)
chaperone cofactor-dependent protein refoldingCyclin-G-associated kinaseHomo sapiens (human)
clathrin coat disassemblyCyclin-G-associated kinaseHomo sapiens (human)
clathrin-dependent endocytosisCyclin-G-associated kinaseHomo sapiens (human)
protein localization to plasma membraneCyclin-G-associated kinaseHomo sapiens (human)
Golgi to lysosome transportCyclin-G-associated kinaseHomo sapiens (human)
regulation of clathrin coat assemblyCyclin-G-associated kinaseHomo sapiens (human)
intracellular signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
type B pancreatic cell development3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of protein kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
hyperosmotic response3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
epidermal growth factor receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
insulin receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of phospholipase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic process3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cell migration3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
calcium-mediated signaling3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
actin cytoskeleton organization3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
T cell costimulation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
activation of protein kinase B activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cellular response to insulin stimulus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of toll-like receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
regulation of canonical NF-kappaB signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
regulation of mast cell degranulation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of angiogenesis3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein autophosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cellular response to epidermal growth factor stimulus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of protein localization to plasma membrane3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of sprouting angiogenesis3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of endothelial cell apoptotic process3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
intracellular signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
chromatin organizationDeath-associated protein kinase 3Homo sapiens (human)
regulation of DNA-templated transcriptionDeath-associated protein kinase 3Homo sapiens (human)
protein phosphorylationDeath-associated protein kinase 3Homo sapiens (human)
apoptotic processDeath-associated protein kinase 3Homo sapiens (human)
regulation of smooth muscle contractionDeath-associated protein kinase 3Homo sapiens (human)
regulation of mitotic nuclear divisionDeath-associated protein kinase 3Homo sapiens (human)
regulation of mitotic cell cycleDeath-associated protein kinase 3Homo sapiens (human)
regulation of cell shapeDeath-associated protein kinase 3Homo sapiens (human)
regulation of autophagyDeath-associated protein kinase 3Homo sapiens (human)
negative regulation of translationDeath-associated protein kinase 3Homo sapiens (human)
positive regulation of cell migrationDeath-associated protein kinase 3Homo sapiens (human)
regulation of actin cytoskeleton organizationDeath-associated protein kinase 3Homo sapiens (human)
intracellular signal transductionDeath-associated protein kinase 3Homo sapiens (human)
regulation of apoptotic processDeath-associated protein kinase 3Homo sapiens (human)
positive regulation of apoptotic processDeath-associated protein kinase 3Homo sapiens (human)
regulation of myosin II filament organizationDeath-associated protein kinase 3Homo sapiens (human)
protein autophosphorylationDeath-associated protein kinase 3Homo sapiens (human)
regulation of focal adhesion assemblyDeath-associated protein kinase 3Homo sapiens (human)
cellular response to type II interferonDeath-associated protein kinase 3Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayDeath-associated protein kinase 3Homo sapiens (human)
apoptotic signaling pathwayDeath-associated protein kinase 3Homo sapiens (human)
regulation of cell motilityDeath-associated protein kinase 3Homo sapiens (human)
endothelial cell proliferationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mRNA catabolic processSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
regulation of macroautophagySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of RNA splicingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to unfolded proteinSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
peptidyl-serine autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-mediated unfolded protein responseSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of JUN kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mRNA splicing, via endonucleolytic cleavage and ligationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to hydrogen peroxideSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to glucose stimulusSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of endoplasmic reticulum unfolded protein responseSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
insulin metabolic processSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
peptidyl-serine trans-autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
negative regulation of cytokine productionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
chromatin remodelingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein phosphorylationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
inflammatory responseRibosomal protein S6 kinase alpha-5Homo sapiens (human)
axon guidanceRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of CREB transcription factor activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
post-translational protein modificationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
negative regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
interleukin-1-mediated signaling pathwayRibosomal protein S6 kinase alpha-5Homo sapiens (human)
regulation of postsynapse organizationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase 16Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 16Homo sapiens (human)
cellular response to transforming growth factor beta stimulusSerine/threonine-protein kinase 16Homo sapiens (human)
kidney developmentReninHomo sapiens (human)
mesonephros developmentReninHomo sapiens (human)
angiotensin maturationReninHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionReninHomo sapiens (human)
proteolysisReninHomo sapiens (human)
regulation of blood pressureReninHomo sapiens (human)
male gonad developmentReninHomo sapiens (human)
hormone-mediated signaling pathwayReninHomo sapiens (human)
response to lipopolysaccharideReninHomo sapiens (human)
response to immobilization stressReninHomo sapiens (human)
drinking behaviorReninHomo sapiens (human)
regulation of MAPK cascadeReninHomo sapiens (human)
cell maturationReninHomo sapiens (human)
amyloid-beta metabolic processReninHomo sapiens (human)
response to cAMPReninHomo sapiens (human)
response to cGMPReninHomo sapiens (human)
cellular response to xenobiotic stimulusReninHomo sapiens (human)
juxtaglomerular apparatus developmentReninHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
glycogen metabolic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
glycogen biosynthetic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
glycogen catabolic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
generation of precursor metabolites and energyPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
protein phosphorylationPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
positive regulation of glycogen catabolic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
positive regulation of cytokine productionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
translationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein phosphorylationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of cell population proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
response to virusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of translationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
endoplasmic reticulum unfolded protein responseInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of chemokine productionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of stress-activated MAPK cascadeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of osteoblast proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cellular response to amino acid starvationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
response to interferon-alphaInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of apoptotic processInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of MAPK cascadeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of viral genome replicationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein autophosphorylationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
defense response to virusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
antiviral innate immune responseInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of NLRP3 inflammasome complex assemblyInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic progenitor cell differentiationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic stem cell proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic stem cell differentiationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
eiF2alpha phosphorylation in response to endoplasmic reticulum stressInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 2Homo sapiens (human)
DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
DNA repairCyclin-dependent kinase 2Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 2Homo sapiens (human)
DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
potassium ion transportCyclin-dependent kinase 2Homo sapiens (human)
centriole replicationCyclin-dependent kinase 2Homo sapiens (human)
Ras protein signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of heterochromatin formationCyclin-dependent kinase 2Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiationCyclin-dependent kinase 2Homo sapiens (human)
telomere maintenance in response to DNA damageCyclin-dependent kinase 2Homo sapiens (human)
post-translational protein modificationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
centrosome duplicationCyclin-dependent kinase 2Homo sapiens (human)
cell divisionCyclin-dependent kinase 2Homo sapiens (human)
meiotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
cellular response to nitric oxideCyclin-dependent kinase 2Homo sapiens (human)
cellular senescenceCyclin-dependent kinase 2Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processCyclin-dependent kinase 2Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 2Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 2Homo sapiens (human)
cell adhesionEphrin type-A receptor 3Homo sapiens (human)
regulation of epithelial to mesenchymal transitionEphrin type-A receptor 3Homo sapiens (human)
positive regulation of neuron projection developmentEphrin type-A receptor 3Homo sapiens (human)
cell migrationEphrin type-A receptor 3Homo sapiens (human)
peptidyl-tyrosine phosphorylationEphrin type-A receptor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationEphrin type-A receptor 3Homo sapiens (human)
regulation of GTPase activityEphrin type-A receptor 3Homo sapiens (human)
negative regulation of endocytosisEphrin type-A receptor 3Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 3Homo sapiens (human)
regulation of focal adhesion assemblyEphrin type-A receptor 3Homo sapiens (human)
regulation of microtubule cytoskeleton organizationEphrin type-A receptor 3Homo sapiens (human)
cellular response to retinoic acidEphrin type-A receptor 3Homo sapiens (human)
fasciculation of sensory neuron axonEphrin type-A receptor 3Homo sapiens (human)
fasciculation of motor neuron axonEphrin type-A receptor 3Homo sapiens (human)
positive regulation of protein localization to plasma membraneEphrin type-A receptor 3Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 3Homo sapiens (human)
axon guidanceEphrin type-A receptor 3Homo sapiens (human)
spindle organizationDual specificity protein kinase TTKHomo sapiens (human)
mitotic spindle organizationDual specificity protein kinase TTKHomo sapiens (human)
positive regulation of cell population proliferationDual specificity protein kinase TTKHomo sapiens (human)
female meiosis chromosome segregationDual specificity protein kinase TTKHomo sapiens (human)
protein localization to meiotic spindle midzoneDual specificity protein kinase TTKHomo sapiens (human)
chromosome segregationDual specificity protein kinase TTKHomo sapiens (human)
peptidyl-serine phosphorylationDual specificity protein kinase TTKHomo sapiens (human)
protein localization to kinetochoreDual specificity protein kinase TTKHomo sapiens (human)
mitotic spindle assembly checkpoint signalingDual specificity protein kinase TTKHomo sapiens (human)
meiotic spindle assembly checkpoint signalingDual specificity protein kinase TTKHomo sapiens (human)
JUN phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
response to UVMitogen-activated protein kinase 8Homo sapiens (human)
negative regulation of apoptotic processMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 8Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
response to oxidative stressMitogen-activated protein kinase 8Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 8Homo sapiens (human)
JUN phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 8Homo sapiens (human)
regulation of macroautophagyMitogen-activated protein kinase 8Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
peptidyl-threonine phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of cell killingMitogen-activated protein kinase 8Homo sapiens (human)
negative regulation of protein bindingMitogen-activated protein kinase 8Homo sapiens (human)
regulation of protein localizationMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to oxidative stressMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 8Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 8Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase 8Homo sapiens (human)
negative regulation of apoptotic processMitogen-activated protein kinase 8Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of protein metabolic processMitogen-activated protein kinase 8Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 8Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 8Homo sapiens (human)
energy homeostasisMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyMitogen-activated protein kinase 8Homo sapiens (human)
response to mechanical stimulusMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of establishment of protein localization to mitochondrionMitogen-activated protein kinase 8Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 9Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiationMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of protein ubiquitinationMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processMitogen-activated protein kinase 9Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 9Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 9Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 9Homo sapiens (human)
modulation of chemical synaptic transmissionMitogen-activated protein kinase 9Homo sapiens (human)
protein localization to tricellular tight junctionMitogen-activated protein kinase 9Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of podosome assemblyMitogen-activated protein kinase 9Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 9Homo sapiens (human)
inflammatory response to woundingMitogen-activated protein kinase 9Homo sapiens (human)
apoptotic signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of apoptotic signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
DNA repairCasein kinase I isoform epsilonHomo sapiens (human)
protein phosphorylationCasein kinase I isoform epsilonHomo sapiens (human)
protein localizationCasein kinase I isoform epsilonHomo sapiens (human)
negative regulation of Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
negative regulation of protein bindingCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform epsilonHomo sapiens (human)
regulation of protein localizationCasein kinase I isoform epsilonHomo sapiens (human)
circadian regulation of gene expressionCasein kinase I isoform epsilonHomo sapiens (human)
regulation of circadian rhythmCasein kinase I isoform epsilonHomo sapiens (human)
circadian behaviorCasein kinase I isoform epsilonHomo sapiens (human)
canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of amyloid-beta formationCasein kinase I isoform epsilonHomo sapiens (human)
cellular response to nerve growth factor stimulusCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of non-canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform epsilonHomo sapiens (human)
endocytosisCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
signal transductionCasein kinase I isoform epsilonHomo sapiens (human)
protein phosphorylationDual specificity protein kinase CLK2Homo sapiens (human)
response to ionizing radiationDual specificity protein kinase CLK2Homo sapiens (human)
regulation of RNA splicingDual specificity protein kinase CLK2Homo sapiens (human)
negative regulation of gluconeogenesisDual specificity protein kinase CLK2Homo sapiens (human)
protein autophosphorylationDual specificity protein kinase CLK2Homo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity protein kinase CLK2Homo sapiens (human)
adaptive immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of dendritic cell cytokine productionTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK3Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
B cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-10 productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-12 productionTyrosine-protein kinase JAK3Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-15-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-4-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-2-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-9-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
T cell homeostasisTyrosine-protein kinase JAK3Homo sapiens (human)
innate immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of FasL productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T-helper 1 cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T cell activationTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of T cell apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of thymocyte apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-2Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-4Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-15Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-9Tyrosine-protein kinase JAK3Homo sapiens (human)
regulation of apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 12Homo sapiens (human)
signal transductionMitogen-activated protein kinase 12Homo sapiens (human)
muscle organ developmentMitogen-activated protein kinase 12Homo sapiens (human)
positive regulation of peptidase activityMitogen-activated protein kinase 12Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 12Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 12Homo sapiens (human)
myoblast differentiationMitogen-activated protein kinase 12Homo sapiens (human)
negative regulation of cell cycleMitogen-activated protein kinase 12Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 12Homo sapiens (human)
regulation of cell cycleMitogen-activated protein kinase 12Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 12Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 10Homo sapiens (human)
signal transductionMitogen-activated protein kinase 10Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 10Homo sapiens (human)
response to light stimulusMitogen-activated protein kinase 10Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 10Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 10Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 10Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 10Homo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
protein phosphorylationCyclin-dependent kinase 16Homo sapiens (human)
exocytosisCyclin-dependent kinase 16Homo sapiens (human)
spermatogenesisCyclin-dependent kinase 16Homo sapiens (human)
positive regulation of autophagyCyclin-dependent kinase 16Homo sapiens (human)
growth hormone secretionCyclin-dependent kinase 16Homo sapiens (human)
neuron projection developmentCyclin-dependent kinase 16Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 16Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusCyclin-dependent kinase 16Homo sapiens (human)
cell morphogenesisSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of protein phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of protein bindingSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase 4Homo sapiens (human)
branching involved in blood vessel morphogenesisSerine/threonine-protein kinase 4Homo sapiens (human)
neural tube formationSerine/threonine-protein kinase 4Homo sapiens (human)
endocardium developmentSerine/threonine-protein kinase 4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein import into nucleusSerine/threonine-protein kinase 4Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
signal transductionSerine/threonine-protein kinase 4Homo sapiens (human)
central nervous system developmentSerine/threonine-protein kinase 4Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsSerine/threonine-protein kinase 4Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
keratinocyte differentiationSerine/threonine-protein kinase 4Homo sapiens (human)
organ growthSerine/threonine-protein kinase 4Homo sapiens (human)
hippo signalingSerine/threonine-protein kinase 4Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of fat cell differentiationSerine/threonine-protein kinase 4Homo sapiens (human)
negative regulation of organ growthSerine/threonine-protein kinase 4Homo sapiens (human)
epithelial cell proliferationSerine/threonine-protein kinase 4Homo sapiens (human)
negative regulation of epithelial cell proliferationSerine/threonine-protein kinase 4Homo sapiens (human)
protein tetramerizationSerine/threonine-protein kinase 4Homo sapiens (human)
canonical Wnt signaling pathwaySerine/threonine-protein kinase 4Homo sapiens (human)
primitive hemopoiesisSerine/threonine-protein kinase 4Homo sapiens (human)
cell differentiation involved in embryonic placenta developmentSerine/threonine-protein kinase 4Homo sapiens (human)
regulation of cell differentiation involved in embryonic placenta developmentSerine/threonine-protein kinase 4Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase 4Homo sapiens (human)
hepatocyte apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptorsSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of hepatocyte apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of substrate-dependent cell migration, cell attachment to substrateSerine/threonine-protein kinase 4Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase 4Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
nucleocytoplasmic transportCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
signal transductionCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
nervous system developmentCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of neuron projection developmentCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
cell differentiationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
negative regulation of protein bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
regulation of protein localizationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
intracellular signal transductionCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
regulation of protein bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of protein export from nucleusCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
regulation of muscle cell differentiationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of muscle cell differentiationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of synapse structural plasticityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of dendritic spine developmentCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
signal transductionRibosomal protein S6 kinase alpha-2Homo sapiens (human)
chemical synaptic transmissionRibosomal protein S6 kinase alpha-2Homo sapiens (human)
negative regulation of cell population proliferationRibosomal protein S6 kinase alpha-2Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-2Homo sapiens (human)
positive regulation of apoptotic processRibosomal protein S6 kinase alpha-2Homo sapiens (human)
negative regulation of cell cycleRibosomal protein S6 kinase alpha-2Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 14Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase 14Homo sapiens (human)
cell morphogenesisMitogen-activated protein kinase 14Homo sapiens (human)
cartilage condensationMitogen-activated protein kinase 14Homo sapiens (human)
angiogenesisMitogen-activated protein kinase 14Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
placenta developmentMitogen-activated protein kinase 14Homo sapiens (human)
response to dietary excessMitogen-activated protein kinase 14Homo sapiens (human)
chondrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusMitogen-activated protein kinase 14Homo sapiens (human)
glucose metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 14Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 14Homo sapiens (human)
signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
skeletal muscle tissue developmentMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myotube differentiationMitogen-activated protein kinase 14Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 14Homo sapiens (human)
fatty acid oxidationMitogen-activated protein kinase 14Homo sapiens (human)
platelet activationMitogen-activated protein kinase 14Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 14Homo sapiens (human)
osteoclast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 14Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
response to muramyl dipeptideMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 14Homo sapiens (human)
response to insulinMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of hippo signalingMitogen-activated protein kinase 14Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMitogen-activated protein kinase 14Homo sapiens (human)
response to muscle stretchMitogen-activated protein kinase 14Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of protein import into nucleusMitogen-activated protein kinase 14Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
glucose importMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of glucose importMitogen-activated protein kinase 14Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
stem cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
striated muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 14Homo sapiens (human)
bone developmentMitogen-activated protein kinase 14Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipoteichoic acidMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to ionizing radiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of brown fat cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 14Homo sapiens (human)
stress-induced premature senescenceMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 14Homo sapiens (human)
regulation of synaptic membrane adhesionMitogen-activated protein kinase 14Homo sapiens (human)
regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast fusionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphorylationAP2-associated protein kinase 1Homo sapiens (human)
regulation of protein localizationAP2-associated protein kinase 1Homo sapiens (human)
positive regulation of Notch signaling pathwayAP2-associated protein kinase 1Homo sapiens (human)
protein stabilizationAP2-associated protein kinase 1Homo sapiens (human)
membrane organizationAP2-associated protein kinase 1Homo sapiens (human)
presynaptic endocytosisAP2-associated protein kinase 1Homo sapiens (human)
regulation of clathrin-dependent endocytosisAP2-associated protein kinase 1Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase MARK2Homo sapiens (human)
neuron migrationSerine/threonine-protein kinase MARK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
positive regulation of neuron projection developmentSerine/threonine-protein kinase MARK2Homo sapiens (human)
Wnt signaling pathwaySerine/threonine-protein kinase MARK2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase MARK2Homo sapiens (human)
activation of protein kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase MARK2Homo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polaritySerine/threonine-protein kinase MARK2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of cytoskeleton organizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
mitochondrion localizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
axon developmentSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of microtubule cytoskeleton organizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
establishment or maintenance of cell polarity regulating cell shapeSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of microtubule bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
inflammatory responseCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
nervous system developmentCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of neuron projection developmentCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of CREB transcription factor activityCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of apoptotic processCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
negative regulation of apoptotic processCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of phagocytosisCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
regulation of dendrite developmentCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of respiratory burstCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
regulation of granulocyte chemotaxisCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of neutrophil chemotaxisCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
MAPK cascadeCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
calcium-mediated signalingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
cellular response to reactive oxygen speciesCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
regulation of protein kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
CAMKK-AMPK signaling cascadeCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
positive regulation of autophagy of mitochondrionCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
mRNA processingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytidine deaminationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
somatic diversification of immunoglobulinsSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
somatic hypermutation of immunoglobulin genesSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
B cell differentiationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
regulation of nuclear cell cycle DNA replicationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
defense response to bacteriumSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
positive regulation of gene expression via chromosomal CpG island demethylationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
isotype switchingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cellular response to lipopolysaccharideSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
DNA cytosine deaminationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
DNA demethylationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytidine to uridine editingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
negative regulation of single stranded viral RNA replication via double stranded DNA intermediateSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
defense response to virusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
apoptotic processSTE20-like serine/threonine-protein kinase Homo sapiens (human)
regulation of cell migrationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cytoplasmic microtubule organizationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
regulation of apoptotic processSTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein autophosphorylationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
regulation of focal adhesion assemblySTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein phosphorylationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
regulation of RNA splicingDual specificity protein kinase CLK4Homo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity protein kinase CLK4Homo sapiens (human)
regulation of translationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cell surface receptor signaling pathwayMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
hemopoiesisMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
intracellular signal transductionMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to arsenic-containing substanceMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein autophosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform gamma-1Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform gamma-1Homo sapiens (human)
signal transductionCasein kinase I isoform gamma-1Homo sapiens (human)
endocytosisCasein kinase I isoform gamma-1Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform gamma-1Homo sapiens (human)
positive regulation of Notch signaling pathwayBMP-2-inducible protein kinaseHomo sapiens (human)
regulation of clathrin-dependent endocytosisBMP-2-inducible protein kinaseHomo sapiens (human)
regulation of bone mineralizationBMP-2-inducible protein kinaseHomo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase pim-2Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase pim-2Homo sapiens (human)
apoptotic mitochondrial changesSerine/threonine-protein kinase pim-2Homo sapiens (human)
response to virusSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
macroautophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of macroautophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-2Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 17AHomo sapiens (human)
apoptotic processSerine/threonine-protein kinase 17AHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 17AHomo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 17AHomo sapiens (human)
positive regulation of fibroblast apoptotic processSerine/threonine-protein kinase 17AHomo sapiens (human)
regulation of reactive oxygen species metabolic processSerine/threonine-protein kinase 17AHomo sapiens (human)
protein phosphorylationDeath-associated protein kinase 2Homo sapiens (human)
apoptotic processDeath-associated protein kinase 2Homo sapiens (human)
regulation of autophagyDeath-associated protein kinase 2Homo sapiens (human)
intracellular signal transductionDeath-associated protein kinase 2Homo sapiens (human)
regulation of apoptotic processDeath-associated protein kinase 2Homo sapiens (human)
anoikisDeath-associated protein kinase 2Homo sapiens (human)
protein autophosphorylationDeath-associated protein kinase 2Homo sapiens (human)
positive regulation of neutrophil chemotaxisDeath-associated protein kinase 2Homo sapiens (human)
positive regulation of eosinophil chemotaxisDeath-associated protein kinase 2Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathwayDeath-associated protein kinase 2Homo sapiens (human)
positive regulation of apoptotic processDeath-associated protein kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein phosphorylationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoskeleton organizationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
response to organonitrogen compoundTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
Wnt signaling pathwayTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
microvillus assemblyTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
actin cytoskeleton organizationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
intracellular signal transductionTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
positive regulation of JNK cascadeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein autophosphorylationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
regulation of dendrite morphogenesisTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein localization to plasma membraneTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
neuron projection morphogenesisTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
regulation of MAPK cascadeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
MAPK cascadeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein phosphorylationAurora kinase CHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase CHomo sapiens (human)
positive regulation of cytokinesisAurora kinase CHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase CHomo sapiens (human)
cell divisionAurora kinase CHomo sapiens (human)
meiotic cell cycleAurora kinase CHomo sapiens (human)
regulation of cytokinesisAurora kinase CHomo sapiens (human)
mitotic spindle organizationAurora kinase CHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
negative regulation of autophagySerine/threonine-protein kinase 38-likeHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 38-likeHomo sapiens (human)
regulation of cellular component organizationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
postsynapse organizationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (117)

Processvia Protein(s)Taxonomy
protein serine/threonine kinase activitySerine/threonine-protein kinase PLK4Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PLK4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PLK4Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase PLK4Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PLK4Homo sapiens (human)
protein kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase AHomo sapiens (human)
protein bindingAurora kinase AHomo sapiens (human)
ATP bindingAurora kinase AHomo sapiens (human)
protein kinase bindingAurora kinase AHomo sapiens (human)
ubiquitin protein ligase bindingAurora kinase AHomo sapiens (human)
histone H3S10 kinase activityAurora kinase AHomo sapiens (human)
protein heterodimerization activityAurora kinase AHomo sapiens (human)
protein serine kinase activityAurora kinase AHomo sapiens (human)
molecular function activator activityAurora kinase AHomo sapiens (human)
protein serine/threonine kinase activityCyclin-G-associated kinaseHomo sapiens (human)
protein bindingCyclin-G-associated kinaseHomo sapiens (human)
ATP bindingCyclin-G-associated kinaseHomo sapiens (human)
cyclin bindingCyclin-G-associated kinaseHomo sapiens (human)
protein-folding chaperone bindingCyclin-G-associated kinaseHomo sapiens (human)
protein serine kinase activityCyclin-G-associated kinaseHomo sapiens (human)
clathrin bindingCyclin-G-associated kinaseHomo sapiens (human)
protein serine/threonine kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
3-phosphoinositide-dependent protein kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
ATP binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
phospholipase activator activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
phospholipase binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein serine kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityDeath-associated protein kinase 3Homo sapiens (human)
protein bindingDeath-associated protein kinase 3Homo sapiens (human)
ATP bindingDeath-associated protein kinase 3Homo sapiens (human)
cAMP response element binding protein bindingDeath-associated protein kinase 3Homo sapiens (human)
small GTPase bindingDeath-associated protein kinase 3Homo sapiens (human)
identical protein bindingDeath-associated protein kinase 3Homo sapiens (human)
protein homodimerization activityDeath-associated protein kinase 3Homo sapiens (human)
leucine zipper domain bindingDeath-associated protein kinase 3Homo sapiens (human)
protein serine kinase activityDeath-associated protein kinase 3Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
RNA endonuclease activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
platelet-derived growth factor receptor bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
enzyme bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Hsp70 protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
ADP bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Hsp90 protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
unfolded protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein tyrosine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H3S10 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H3S28 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H2AS1 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingSerine/threonine-protein kinase 16Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activitySerine/threonine-protein kinase 16Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 16Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 16Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 16Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 16Homo sapiens (human)
aspartic-type endopeptidase activityReninHomo sapiens (human)
signaling receptor bindingReninHomo sapiens (human)
insulin-like growth factor receptor bindingReninHomo sapiens (human)
protein bindingReninHomo sapiens (human)
peptidase activityReninHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein serine/threonine kinase activityPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
phosphorylase kinase activityPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
protein bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
calmodulin bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
ATP bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
enzyme bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
tau-protein kinase activityPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
RNA bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
double-stranded RNA bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
ATP bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein phosphatase regulator activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
identical protein bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein serine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
histone kinase activityCyclin-dependent kinase 2Homo sapiens (human)
magnesium ion bindingCyclin-dependent kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein bindingCyclin-dependent kinase 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase 2Homo sapiens (human)
protein domain specific bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
ephrin receptor activityEphrin type-A receptor 3Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 3Homo sapiens (human)
protein bindingEphrin type-A receptor 3Homo sapiens (human)
ATP bindingEphrin type-A receptor 3Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 3Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein bindingDual specificity protein kinase TTKHomo sapiens (human)
ATP bindingDual specificity protein kinase TTKHomo sapiens (human)
identical protein bindingDual specificity protein kinase TTKHomo sapiens (human)
kinetochore bindingDual specificity protein kinase TTKHomo sapiens (human)
protein serine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 8Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 8Homo sapiens (human)
protein bindingMitogen-activated protein kinase 8Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 8Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 8Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 8Homo sapiens (human)
histone deacetylase regulator activityMitogen-activated protein kinase 8Homo sapiens (human)
histone deacetylase bindingMitogen-activated protein kinase 8Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 8Homo sapiens (human)
protein serine/threonine kinase bindingMitogen-activated protein kinase 8Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
protein bindingMitogen-activated protein kinase 9Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 9Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
RNA bindingCasein kinase I isoform epsilonHomo sapiens (human)
protein kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
protein bindingCasein kinase I isoform epsilonHomo sapiens (human)
ATP bindingCasein kinase I isoform epsilonHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
protein bindingDual specificity protein kinase CLK2Homo sapiens (human)
ATP bindingDual specificity protein kinase CLK2Homo sapiens (human)
identical protein bindingDual specificity protein kinase CLK2Homo sapiens (human)
protein serine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
protein bindingTyrosine-protein kinase JAK3Homo sapiens (human)
ATP bindingTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor bindingTyrosine-protein kinase JAK3Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase 12Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
protein bindingMitogen-activated protein kinase 12Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 12Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
protein bindingMitogen-activated protein kinase 10Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 10Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 16Homo sapiens (human)
protein bindingCyclin-dependent kinase 16Homo sapiens (human)
ATP bindingCyclin-dependent kinase 16Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 16Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 16Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 4Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 4Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 4Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 4Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase 4Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase 4Homo sapiens (human)
protein serine/threonine kinase activator activitySerine/threonine-protein kinase 4Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingSerine/threonine-protein kinase 4Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 4Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-2Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 14Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 14Homo sapiens (human)
mitogen-activated protein kinase p38 bindingMitogen-activated protein kinase 14Homo sapiens (human)
NFAT protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein serine/threonine kinase activityAP2-associated protein kinase 1Homo sapiens (human)
Notch bindingAP2-associated protein kinase 1Homo sapiens (human)
protein bindingAP2-associated protein kinase 1Homo sapiens (human)
ATP bindingAP2-associated protein kinase 1Homo sapiens (human)
AP-2 adaptor complex bindingAP2-associated protein kinase 1Homo sapiens (human)
protein serine kinase activityAP2-associated protein kinase 1Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
RNA bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
lipid bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
protein kinase activator activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein tyrosine kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
calcium ion bindingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
cytidine deaminase activitySingle-stranded DNA cytosine deaminaseHomo sapiens (human)
protein bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
zinc ion bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
ubiquitin protein ligase bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
identical protein bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
RNA bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
protein serine/threonine kinase activitySTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
ATP bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
identical protein bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein homodimerization activitySTE20-like serine/threonine-protein kinase Homo sapiens (human)
cadherin bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein serine kinase activitySTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein bindingDual specificity protein kinase CLK4Homo sapiens (human)
ATP bindingDual specificity protein kinase CLK4Homo sapiens (human)
protein serine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
ATP bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
metal ion bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein serine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calmodulin bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform gamma-1Homo sapiens (human)
protein bindingCasein kinase I isoform gamma-1Homo sapiens (human)
ATP bindingCasein kinase I isoform gamma-1Homo sapiens (human)
protein serine kinase activityCasein kinase I isoform gamma-1Homo sapiens (human)
protein bindingBMP-2-inducible protein kinaseHomo sapiens (human)
ATP bindingBMP-2-inducible protein kinaseHomo sapiens (human)
protein serine kinase activityBMP-2-inducible protein kinaseHomo sapiens (human)
phosphatase regulator activityBMP-2-inducible protein kinaseHomo sapiens (human)
AP-2 adaptor complex bindingBMP-2-inducible protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityBMP-2-inducible protein kinaseHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 17AHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 17AHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 17AHomo sapiens (human)
protein serine/threonine kinase activityDeath-associated protein kinase 2Homo sapiens (human)
protein bindingDeath-associated protein kinase 2Homo sapiens (human)
calmodulin bindingDeath-associated protein kinase 2Homo sapiens (human)
ATP bindingDeath-associated protein kinase 2Homo sapiens (human)
identical protein bindingDeath-associated protein kinase 2Homo sapiens (human)
protein serine kinase activityDeath-associated protein kinase 2Homo sapiens (human)
protein kinase activityTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein bindingTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
ATP bindingTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein serine kinase activityTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein kinase activityAurora kinase CHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase CHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase CHomo sapiens (human)
protein bindingAurora kinase CHomo sapiens (human)
ATP bindingAurora kinase CHomo sapiens (human)
protein serine kinase activityAurora kinase CHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
actin bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 38-likeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (119)

Processvia Protein(s)Taxonomy
XY bodySerine/threonine-protein kinase PLK4Homo sapiens (human)
nucleolusSerine/threonine-protein kinase PLK4Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK4Homo sapiens (human)
centrioleSerine/threonine-protein kinase PLK4Homo sapiens (human)
cytosolSerine/threonine-protein kinase PLK4Homo sapiens (human)
cleavage furrowSerine/threonine-protein kinase PLK4Homo sapiens (human)
deuterosomeSerine/threonine-protein kinase PLK4Homo sapiens (human)
procentrioleSerine/threonine-protein kinase PLK4Homo sapiens (human)
procentriole replication complexSerine/threonine-protein kinase PLK4Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK4Homo sapiens (human)
spindle microtubuleAurora kinase AHomo sapiens (human)
nucleusAurora kinase AHomo sapiens (human)
nucleoplasmAurora kinase AHomo sapiens (human)
centrosomeAurora kinase AHomo sapiens (human)
centrioleAurora kinase AHomo sapiens (human)
spindleAurora kinase AHomo sapiens (human)
cytosolAurora kinase AHomo sapiens (human)
postsynaptic densityAurora kinase AHomo sapiens (human)
microtubule cytoskeletonAurora kinase AHomo sapiens (human)
basolateral plasma membraneAurora kinase AHomo sapiens (human)
midbodyAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
ciliary basal bodyAurora kinase AHomo sapiens (human)
germinal vesicleAurora kinase AHomo sapiens (human)
axon hillockAurora kinase AHomo sapiens (human)
pronucleusAurora kinase AHomo sapiens (human)
perinuclear region of cytoplasmAurora kinase AHomo sapiens (human)
mitotic spindleAurora kinase AHomo sapiens (human)
meiotic spindleAurora kinase AHomo sapiens (human)
mitotic spindle poleAurora kinase AHomo sapiens (human)
glutamatergic synapseAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
chromosome passenger complexAurora kinase AHomo sapiens (human)
spindle midzoneAurora kinase AHomo sapiens (human)
kinetochoreAurora kinase AHomo sapiens (human)
Golgi apparatusCyclin-G-associated kinaseHomo sapiens (human)
cytosolCyclin-G-associated kinaseHomo sapiens (human)
focal adhesionCyclin-G-associated kinaseHomo sapiens (human)
membraneCyclin-G-associated kinaseHomo sapiens (human)
clathrin-coated vesicleCyclin-G-associated kinaseHomo sapiens (human)
vesicleCyclin-G-associated kinaseHomo sapiens (human)
intracellular membrane-bounded organelleCyclin-G-associated kinaseHomo sapiens (human)
perinuclear region of cytoplasmCyclin-G-associated kinaseHomo sapiens (human)
presynapseCyclin-G-associated kinaseHomo sapiens (human)
vesicleCyclin-G-associated kinaseHomo sapiens (human)
cytoplasmCyclin-G-associated kinaseHomo sapiens (human)
intracellular membrane-bounded organelleCyclin-G-associated kinaseHomo sapiens (human)
nucleus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasm3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytosol3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
plasma membrane3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
focal adhesion3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
postsynaptic density3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasmic vesicle3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cell projection3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
nucleusDeath-associated protein kinase 3Homo sapiens (human)
nucleoplasmDeath-associated protein kinase 3Homo sapiens (human)
cytosolDeath-associated protein kinase 3Homo sapiens (human)
PML bodyDeath-associated protein kinase 3Homo sapiens (human)
nucleusDeath-associated protein kinase 3Homo sapiens (human)
cytoplasmDeath-associated protein kinase 3Homo sapiens (human)
nuclear inner membraneSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Ire1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
AIP1-IRE1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-TRAF2-ASK1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-RACK1-PP2A complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
nucleusRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 16Homo sapiens (human)
Golgi-associated vesicleSerine/threonine-protein kinase 16Homo sapiens (human)
cytosolSerine/threonine-protein kinase 16Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase 16Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase 16Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 16Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 16Homo sapiens (human)
extracellular regionReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
plasma membraneReninHomo sapiens (human)
apical part of cellReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
phosphorylase kinase complexPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
nucleoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cytosolInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
ribosomeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
membraneInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
perinuclear region of cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
nucleusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
chromosome, telomeric regionCyclin-dependent kinase 2Homo sapiens (human)
condensed chromosomeCyclin-dependent kinase 2Homo sapiens (human)
X chromosomeCyclin-dependent kinase 2Homo sapiens (human)
Y chromosomeCyclin-dependent kinase 2Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
nuclear envelopeCyclin-dependent kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
endosomeCyclin-dependent kinase 2Homo sapiens (human)
centrosomeCyclin-dependent kinase 2Homo sapiens (human)
cytosolCyclin-dependent kinase 2Homo sapiens (human)
Cajal bodyCyclin-dependent kinase 2Homo sapiens (human)
cyclin A1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin A2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 2Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
extracellular regionEphrin type-A receptor 3Homo sapiens (human)
nucleoplasmEphrin type-A receptor 3Homo sapiens (human)
early endosomeEphrin type-A receptor 3Homo sapiens (human)
cytosolEphrin type-A receptor 3Homo sapiens (human)
plasma membraneEphrin type-A receptor 3Homo sapiens (human)
actin cytoskeletonEphrin type-A receptor 3Homo sapiens (human)
nuclear membraneEphrin type-A receptor 3Homo sapiens (human)
dendriteEphrin type-A receptor 3Homo sapiens (human)
plasma membraneEphrin type-A receptor 3Homo sapiens (human)
cytoplasmDual specificity protein kinase TTKHomo sapiens (human)
spindleDual specificity protein kinase TTKHomo sapiens (human)
membraneDual specificity protein kinase TTKHomo sapiens (human)
kinetochoreDual specificity protein kinase TTKHomo sapiens (human)
nucleusDual specificity protein kinase TTKHomo sapiens (human)
cytoplasmMitogen-activated protein kinase 8Homo sapiens (human)
nucleusMitogen-activated protein kinase 8Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 8Homo sapiens (human)
cytosolMitogen-activated protein kinase 8Homo sapiens (human)
axonMitogen-activated protein kinase 8Homo sapiens (human)
synapseMitogen-activated protein kinase 8Homo sapiens (human)
basal dendriteMitogen-activated protein kinase 8Homo sapiens (human)
nucleusMitogen-activated protein kinase 8Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 9Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 9Homo sapiens (human)
cytosolMitogen-activated protein kinase 9Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 9Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 9Homo sapiens (human)
Schaffer collateral - CA1 synapseMitogen-activated protein kinase 9Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 9Homo sapiens (human)
nucleusMitogen-activated protein kinase 9Homo sapiens (human)
nucleusCasein kinase I isoform epsilonHomo sapiens (human)
nucleoplasmCasein kinase I isoform epsilonHomo sapiens (human)
cytoplasmCasein kinase I isoform epsilonHomo sapiens (human)
cytosolCasein kinase I isoform epsilonHomo sapiens (human)
growth coneCasein kinase I isoform epsilonHomo sapiens (human)
neuronal cell bodyCasein kinase I isoform epsilonHomo sapiens (human)
ribonucleoprotein complexCasein kinase I isoform epsilonHomo sapiens (human)
cytoplasmCasein kinase I isoform epsilonHomo sapiens (human)
nucleusCasein kinase I isoform epsilonHomo sapiens (human)
nucleusDual specificity protein kinase CLK2Homo sapiens (human)
nucleoplasmDual specificity protein kinase CLK2Homo sapiens (human)
nuclear bodyDual specificity protein kinase CLK2Homo sapiens (human)
nuclear speckDual specificity protein kinase CLK2Homo sapiens (human)
nucleusDual specificity protein kinase CLK2Homo sapiens (human)
extrinsic component of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
endosomeTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
cytoskeletonTyrosine-protein kinase JAK3Homo sapiens (human)
plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 12Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 12Homo sapiens (human)
cytosolMitogen-activated protein kinase 12Homo sapiens (human)
nucleusMitogen-activated protein kinase 12Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 12Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 10Homo sapiens (human)
cytosolMitogen-activated protein kinase 10Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 10Homo sapiens (human)
nucleusMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
synaptic vesicleCyclin-dependent kinase 16Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmCyclin-dependent kinase 16Homo sapiens (human)
cytosolCyclin-dependent kinase 16Homo sapiens (human)
plasma membraneCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmic side of plasma membraneCyclin-dependent kinase 16Homo sapiens (human)
microtubule cytoskeletonCyclin-dependent kinase 16Homo sapiens (human)
neuron projectionCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmCyclin-dependent kinase 16Homo sapiens (human)
nucleusCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 4Homo sapiens (human)
nucleusSerine/threonine-protein kinase 4Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 4Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 4Homo sapiens (human)
cytosolSerine/threonine-protein kinase 4Homo sapiens (human)
nuclear bodySerine/threonine-protein kinase 4Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase 4Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
intracellular anatomical structureCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
nucleusRibosomal protein S6 kinase alpha-2Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-2Homo sapiens (human)
synapseRibosomal protein S6 kinase alpha-2Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
spindle poleMitogen-activated protein kinase 14Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 14Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 14Homo sapiens (human)
secretory granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 14Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
cytosolAP2-associated protein kinase 1Homo sapiens (human)
plasma membraneAP2-associated protein kinase 1Homo sapiens (human)
clathrin-coated pitAP2-associated protein kinase 1Homo sapiens (human)
clathrin-coated vesicleAP2-associated protein kinase 1Homo sapiens (human)
cell leading edgeAP2-associated protein kinase 1Homo sapiens (human)
terminal boutonAP2-associated protein kinase 1Homo sapiens (human)
intracellular membrane-bounded organelleAP2-associated protein kinase 1Homo sapiens (human)
presynapseAP2-associated protein kinase 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase MARK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase MARK2Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase MARK2Homo sapiens (human)
actin filamentSerine/threonine-protein kinase MARK2Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase MARK2Homo sapiens (human)
membraneSerine/threonine-protein kinase MARK2Homo sapiens (human)
lateral plasma membraneSerine/threonine-protein kinase MARK2Homo sapiens (human)
dendriteSerine/threonine-protein kinase MARK2Homo sapiens (human)
microtubule bundleSerine/threonine-protein kinase MARK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase MARK2Homo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
intracellular anatomical structureCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
Golgi membraneCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
plasma membraneCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
intracellular anatomical structureCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
nucleusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytoplasmSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytosolSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
protein-containing complexSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
nucleusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytoplasmSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
P-bodySingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytoplasmSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cytosolSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cell leading edgeSTE20-like serine/threonine-protein kinase Homo sapiens (human)
perinuclear region of cytoplasmSTE20-like serine/threonine-protein kinase Homo sapiens (human)
extracellular exosomeSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cytoplasmSTE20-like serine/threonine-protein kinase Homo sapiens (human)
nucleusDual specificity protein kinase CLK4Homo sapiens (human)
nucleoplasmMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nuclear bodyMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
PML bodyMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nucleusMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytosolCasein kinase I isoform gamma-1Homo sapiens (human)
nucleusCasein kinase I isoform gamma-1Homo sapiens (human)
plasma membraneCasein kinase I isoform gamma-1Homo sapiens (human)
cytoplasmCasein kinase I isoform gamma-1Homo sapiens (human)
nuclear speckBMP-2-inducible protein kinaseHomo sapiens (human)
cytoplasmBMP-2-inducible protein kinaseHomo sapiens (human)
nucleusBMP-2-inducible protein kinaseHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-2Homo sapiens (human)
nucleusSerine/threonine-protein kinase 17AHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase 17AHomo sapiens (human)
nuclear speckSerine/threonine-protein kinase 17AHomo sapiens (human)
nucleusSerine/threonine-protein kinase 17AHomo sapiens (human)
cytoplasmDeath-associated protein kinase 2Homo sapiens (human)
Golgi apparatusDeath-associated protein kinase 2Homo sapiens (human)
cytoplasmic vesicleDeath-associated protein kinase 2Homo sapiens (human)
autophagosome lumenDeath-associated protein kinase 2Homo sapiens (human)
intracellular membrane-bounded organelleDeath-associated protein kinase 2Homo sapiens (human)
cytoplasmDeath-associated protein kinase 2Homo sapiens (human)
nucleusDeath-associated protein kinase 2Homo sapiens (human)
nucleusTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
nucleoplasmTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoplasmTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytosolTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoskeletonTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
apical plasma membraneTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
recycling endosomeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
extracellular exosomeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
presynapseTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
glutamatergic synapseTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
postsynaptic density, intracellular componentTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoplasmTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
condensed chromosomeAurora kinase CHomo sapiens (human)
nucleusAurora kinase CHomo sapiens (human)
cytoplasmAurora kinase CHomo sapiens (human)
spindleAurora kinase CHomo sapiens (human)
midbodyAurora kinase CHomo sapiens (human)
spindle midzoneAurora kinase CHomo sapiens (human)
chromosome passenger complexAurora kinase CHomo sapiens (human)
kinetochoreAurora kinase CHomo sapiens (human)
spindle midzoneAurora kinase CHomo sapiens (human)
spindle pole centrosomeAurora kinase CHomo sapiens (human)
spindle microtubuleAurora kinase CHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase 38-likeHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase 38-likeHomo sapiens (human)
cytosolSerine/threonine-protein kinase 38-likeHomo sapiens (human)
actin cytoskeletonSerine/threonine-protein kinase 38-likeHomo sapiens (human)
membraneSerine/threonine-protein kinase 38-likeHomo sapiens (human)
glutamatergic synapseSerine/threonine-protein kinase 38-likeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (926)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1224762Delta TM value showing the stabilisation of CLK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1552053Inhibition of MPS1 (unknown origin)2019European journal of medicinal chemistry, Aug-01, Volume: 175Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.
AID1861927Antiproliferative activity against human Hs-578T cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861893Antiproliferative activity against human SW-620 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861894Antiproliferative activity against human SF-268 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224800Delta TM value showing the stabilisation of MST4 (2) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861889Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861923Antiproliferative activity against human PC-3 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224794Delta TM value showing the stabilisation of RSK2b produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861897Antiproliferative activity against human SNB-19 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224769Delta TM value showing the stabilisation of GSK3B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861915Antiproliferative activity against human 786-0 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224757Delta TM value showing the stabilisation of CDK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224779Delta TM value showing the stabilisation of NEK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861906Antiproliferative activity against human UACC-257 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861912Antiproliferative activity against human OVCAR-8 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861903Antiproliferative activity against human SK-MEL-2 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224786Delta TM value showing the stabilisation of PIM1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861928Antiproliferative activity against human BT-549 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224748Delta TM value showing the stabilisation of AMPKA2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861946Inhibition of FLT4 (unknown origin)2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861886Antiproliferative activity against human NCI-H522 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224784Delta TM value showing the stabilisation of PCTK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861880Antiproliferative activity against human HOP-62 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861921Antiproliferative activity against human TK-10 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224796Delta TM value showing the stabilisation of LOK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224768Delta TM value showing the stabilisation of DMPK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224783Delta TM value showing the stabilisation of PAK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861907Antiproliferative activity against human UACC-62 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224775Delta TM value showing the stabilisation of ERK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224792Delta TM value showing the stabilisation of RIOK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861876Antiproliferative activity against human RPMI-8226 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861908Antiproliferative activity against human IGROV-1 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1869026Inhibition of LPS-induced JNK MAPK phosphorylation in mouse RAW264.7 cells pretreated with compound for 2 hrs followed by LPS-stimulation and measured after 30 mins by Western blot analysis2022Bioorganic & medicinal chemistry, 07-15, Volume: 66Discovery of diarylheptanoids that activate α7 nAchR-JAK2-STAT3 signaling in macrophages with anti-inflammatory activity in vitro and in vivo.
AID1739949Inhibition of human JNK1alpha1 at 10 uM after 40 mins by [gamma-33ATP] radiometric assay relative to control2020European journal of medicinal chemistry, Sep-01, Volume: 201Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors.
AID1861892Antiproliferative activity against human KM12 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861905Antiproliferative activity against human SK-MEL-5 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861872Antiproliferative activity against human CCRF-CEM cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224751Delta TM value showing the stabilisation of CAMK2A produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1739950Inhibition of human JNK3 at 10 uM after 40 mins by [gamma-33ATP] radiometric assay relative to control2020European journal of medicinal chemistry, Sep-01, Volume: 201Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors.
AID1889885Inhibition of JNK3 (unknown origin)2022Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases.
AID1861922Antiproliferative activity against human UO-31 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224801Delta TM value showing the stabilisation of MST1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861873Antiproliferative activity against human HL-60(TB) cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861890Antiproliferative activity against human HCT-15 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224788Delta TM value showing the stabilisation of PIM3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861885Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1530260Binding affinity to human partial length JNK3 (V28 to Q422 residues) expressed in HEK293 cells measured after 1 hr by Kinomescan method2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis, biological evaluation, and molecular modeling of 11H-indeno[1,2-b]quinoxalin-11-one derivatives and tryptanthrin-6-oxime as c-Jun N-terminal kinase inhibitors.
AID1224780Delta TM value showing the stabilisation of OSR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224753Delta TM value showing the stabilisation of CAMK2D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861918Antiproliferative activity against human CAKI-1 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1739955Inhibition of human JNK2alpha2 at 30 uM after 40 mins by [gamma-33ATP] radiometric assay relative to control2020European journal of medicinal chemistry, Sep-01, Volume: 201Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors.
AID1861879Antiproliferative activity against human EKVX cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1530259Binding affinity to human full-length JNK2 (M1 to Q382 residues) expressed in HEK293 cells measured after 1 hr by Kinomescan method2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis, biological evaluation, and molecular modeling of 11H-indeno[1,2-b]quinoxalin-11-one derivatives and tryptanthrin-6-oxime as c-Jun N-terminal kinase inhibitors.
AID1224754Delta TM value showing the stabilisation of CAMK2G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861919Antiproliferative activity against human RXF 393 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224767Delta TM value showing the stabilisation of DAPK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861920Antiproliferative activity against human SN12C cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1889884Inhibition of JNK1 (unknown origin)2022Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases.
AID1861924Antiproliferative activity against human DU-145 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861911Antiproliferative activity against human OVCAR-5 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224765Delta TM value showing the stabilisation of CK1G2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861904Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1876280Inhibition of JNK3 (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID1224759Delta TM value showing the stabilisation of CDKL1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224755Delta TM value showing the stabilisation of CAMK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861898Antiproliferative activity against human SNB-75 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1530274Inhibition of JNK in human MONO-MAC-6 cells assessed as reduction in LPS-induced IL6 production preincubated for 30 mins followed by LPS-stimulation and measured after 24 hrs by ELISA2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis, biological evaluation, and molecular modeling of 11H-indeno[1,2-b]quinoxalin-11-one derivatives and tryptanthrin-6-oxime as c-Jun N-terminal kinase inhibitors.
AID1224782Delta TM value showing the stabilisation of PAK5 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861913Antiproliferative activity against human NCI-ADR-RES cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224805Delta TM value showing the stabilisation of VRK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1739956Inhibition of human JNK2alpha2 at 100 uM after 40 mins by [gamma-33ATP] radiometric assay relative to control2020European journal of medicinal chemistry, Sep-01, Volume: 201Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors.
AID1861877Antiproliferative activity against human SR cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224752Delta TM value showing the stabilisation of CAMK2B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224798Delta TM value showing the stabilisation of DRAK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861888Antiproliferative activity against human HCC 2998 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861899Antiproliferative activity against human U-251 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861878Antiproliferative activity against human A549 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861881Antiproliferative activity against human HOP-92 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861945Inhibition of JNK3 (unknown origin)2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861875Antiproliferative activity against human MOLT-4 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861917Antiproliferative activity against human ACHN cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861874Antiproliferative activity against human K562 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861891Antiproliferative activity against human HT-29 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861896Antiproliferative activity against human SF-539 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224749Delta TM value showing the stabilisation of CAMK1D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861930Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224761Delta TM value showing the stabilisation of CLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224791Delta TM value showing the stabilisation of PRKACA produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861882Antiproliferative activity against human NCI-H226 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861887Antiproliferative activity against human COLO 205 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224804Delta TM value showing the stabilisation of VRK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224764Delta TM value showing the stabilisation of CK1G1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1530272Inhibition of JNK in human THP1-Blue cells assessed as reduction in LPS-induced NFkappaB/AP1 activation preincubated for 30 mins followed by LPS-stimulation and measured after 24 hrs by quanti-blue staining based alkaline phosphatase reporter gene assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis, biological evaluation, and molecular modeling of 11H-indeno[1,2-b]quinoxalin-11-one derivatives and tryptanthrin-6-oxime as c-Jun N-terminal kinase inhibitors.
AID1861909Antiproliferative activity against human OVCAR-3 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224773Delta TM value showing the stabilisation of ASK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861884Antiproliferative activity against human NCI-H322M cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861914Antiproliferative activity against human SK-OV-3 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224771Delta TM value showing the stabilisation of MEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861895Antiproliferative activity against human SF-295 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224803Delta TM value showing the stabilisation of PBK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1739953Inhibition of human JNK1alpha1 at 100 uM after 40 mins by [gamma-33ATP] radiometric assay relative to control2020European journal of medicinal chemistry, Sep-01, Volume: 201Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors.
AID1224766Delta TM value showing the stabilisation of CK1G3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224787Delta TM value showing the stabilisation of PIM2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224806Delta TM value showing the stabilisation of VRK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861929Antiproliferative activity against human T47D cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224793Delta TM value showing the stabilisation of RSK2a produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224763Delta TM value showing the stabilisation of CLK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861902Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861916Antiproliferative activity against human A498 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224790Delta TM value showing the stabilisation of PLK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224776Delta TM value showing the stabilisation of ERK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861883Antiproliferative activity against human NCI-H23 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861925Antiproliferative activity against human MCF7 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224770Delta TM value showing the stabilisation of JAK1~B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1889887Inhibition of JNK2 (unknown origin)2022Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases.
AID1530258Binding affinity to human full-length JNK1 (M1 to Q384 residues) expressed in HEK293 cells measured after 1 hr by Kinomescan method2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis, biological evaluation, and molecular modeling of 11H-indeno[1,2-b]quinoxalin-11-one derivatives and tryptanthrin-6-oxime as c-Jun N-terminal kinase inhibitors.
AID1224774Delta TM value showing the stabilisation of p38beta produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224807Delta TM value showing the stabilisation of YSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1629277Antiparasitic activity against bloodstream form of Trypanosoma brucei 221 infected in mouse VSMC assessed as parasitic proliferation at 1 uM after 48 hrs by luciferase reporter gene assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor.
AID1224772Delta TM value showing the stabilisation of MAP2K6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1739954Inhibition of human JNK2alpha2 at 10 uM after 40 mins by [gamma-33ATP] radiometric assay relative to control2020European journal of medicinal chemistry, Sep-01, Volume: 201Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors.
AID1224789Delta TM value showing the stabilisation of PLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224799Delta TM value showing the stabilisation of NDR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224758Delta TM value showing the stabilisation of CDK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861900Antiproliferative activity against human Malme-3M cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224785Delta TM value showing the stabilisation of PDK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1739951Inhibition of human JNK3 after 40 mins by [gamma-33ATP] radiometric assay relative to control2020European journal of medicinal chemistry, Sep-01, Volume: 201Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors.
AID1629276Antiparasitic activity against bloodstream form of Trypanosoma brucei 221 infected in mouse VSMC assessed as reduction in log10 RLU at 1 uM after 48 hrs by luciferase reporter gene assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor.
AID1861926Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1861910Antiproliferative activity against human OVCAR-4 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1876279Inhibition of JNK1/2 (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID1224781Delta TM value showing the stabilisation of PAK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861934Antiproliferative activity against human WI-38 cells measured by MTT assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224802Delta TM value showing the stabilisation of TNIK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224750Delta TM value showing the stabilisation of CAMK1G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1629278Antiparasitic activity against bloodstream form of Trypanosoma brucei 221 infected in mouse VSMC assessed as reduction in parasitic proliferation after 48 hrs by cell titer-glo based assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor.
AID1224760Delta TM value showing the stabilisation of CHEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224778Delta TM value showing the stabilisation of NEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224756Delta TM value showing the stabilisation of CAMKK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1861901Antiproliferative activity against human M14 cells measured after 48 hrs by SRB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 69Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
AID1224795Delta TM value showing the stabilisation of SLK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1739952Inhibition of human JNK1alpha1 at 30 uM after 40 mins by [gamma-33ATP] radiometric assay relative to control2020European journal of medicinal chemistry, Sep-01, Volume: 201Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors.
AID1224777Delta TM value showing the stabilisation of MST4(1) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224797Delta TM value showing the stabilisation of MPSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID720075Millipore: Percentage of residual kinase activity of CHEK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID473195Inhibition of JNK12010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Small molecule JNK (c-Jun N-terminal kinase) inhibitors.
AID720398Millipore: Percentage of residual kinase activity of TEC at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID740245Inhibition of JNK3 in human SH-SY5Y cells assessed as blockade of anisomycin-induced c-jun phosphorylation at ser73 at 10 uM incubated for 1 hr prior to anisomycin induction measured after 30 mins by immunoblot analysis2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects.
AID720088Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720434Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP122013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720282Millipore: Percentage of residual kinase activity of SYK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720442Millipore: Percentage of residual kinase activity of NLK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1189542Inhibition of JNK3 (unknown origin) by time-resolved fluorescence assay2015Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1
Inhibitors of c-Jun N-terminal kinases: an update.
AID473196Inhibition of JNK22010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Small molecule JNK (c-Jun N-terminal kinase) inhibitors.
AID435734Percentage NEK6 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720116Millipore: Percentage of residual kinase activity of DMPK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1189541Inhibition of JNK2 (unknown origin) by time-resolved fluorescence assay2015Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1
Inhibitors of c-Jun N-terminal kinases: an update.
AID720263Millipore: Percentage of residual kinase activity of MAPK12 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720135Millipore: Percentage of residual kinase activity of EPHA8 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720470Millipore: Percentage of residual kinase activity of AKT3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720059Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720152Millipore: Percentage of residual kinase activity of FGFR2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720413Millipore: Percentage of residual kinase activity of VRK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720142Millipore: Percentage of residual kinase activity of EPHB3 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720023Millipore: Percentage of residual kinase activity of PRKAA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720429Millipore: Percentage of residual kinase activity of SRC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720325Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435995Percentage SRPK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720181Millipore: Percentage of residual kinase activity of GSK3A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720037Millipore: Percentage of residual kinase activity of AURKB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720368Millipore: Percentage of residual kinase activity of RPS6KA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720377Millipore: Percentage of residual kinase activity of STK24 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720111Millipore: Percentage of residual kinase activity of DCLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256598Average Binding Constant for FRK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720471Millipore: Percentage of residual kinase activity of AKT3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720451Millipore: Percentage of residual kinase activity of PAK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720477Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720069Millipore: Percentage of residual kinase activity of CDK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720427Millipore: Percentage of residual kinase activity of KIT at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256606Average Binding Constant for STK16; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720020Millipore: Percentage of residual kinase activity of ALK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720460Millipore: Percentage of residual kinase activity of PDGFRB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720410Millipore: Percentage of residual kinase activity of ULK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID586672Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with p38 inhibitor SB203580 for 1 hr before compound addition by Western blot analysis2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Involvement of heme oxygenase-1 induction via Nrf2/ARE activation in protection against H2O2-induced PC12 cell death by a metabolite of sesamin contained in sesame seeds.
AID720220Millipore: Percentage of residual kinase activity of PHKG2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720289Millipore: Percentage of residual kinase activity of TAOK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720133Millipore: Percentage of residual kinase activity of EPHA7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720087Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720184Millipore: Percentage of residual kinase activity of GSK3B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720126Millipore: Percentage of residual kinase activity of EPHA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720468Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720350Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435883Percentage SGK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720102Millipore: Percentage of residual kinase activity of CAMK2D at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435738Percentage p38delta MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID256562Average Binding Constant for PAK4; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256593Average Binding Constant for NEK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID436072Percentage CK1delta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720249Millipore: Percentage of residual kinase activity of TYRO3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID720337Millipore: Percentage of residual kinase activity of LYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720404Millipore: Percentage of residual kinase activity of NTRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720388Millipore: Percentage of residual kinase activity of NEK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720465Millipore: Percentage of residual kinase activity of PRKACA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435713Percentage CHK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID617675Inhibition of TNF-alpha-induced c-JUN phosphorylation in mouse B16-F10 cells by TR-FRET assay2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor.
AID720244Millipore: Percentage of residual kinase activity of MST1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256633Average Binding Constant for PRKACA; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256597Average Binding Constant for CLK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720324Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720124Millipore: Percentage of residual kinase activity of EPHA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435727Percentage JNK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435539Percentage PHK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID256603Average Binding Constant for FER; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720284Millipore: Percentage of residual kinase activity of MAP3K7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720163Millipore: Percentage of residual kinase activity of FLT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720405Millipore: Percentage of residual kinase activity of NTRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435350Percentage ERK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720030Millipore: Percentage of residual kinase activity of MAP3K5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720107Millipore: Percentage of residual kinase activity of DAPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720318Millipore: Percentage of residual kinase activity of MAPK8 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256592Average Binding Constant for LIMK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720288Millipore: Percentage of residual kinase activity of TAOK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720230Millipore: Percentage of residual kinase activity of PLK3 at 1uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436037Percentage MAPKAPK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID256602Average Binding Constant for EPHA2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720287Millipore: Percentage of residual kinase activity of TAOK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720040Millipore: Percentage of residual kinase activity of AURKC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720271Millipore: Percentage of residual kinase activity of SGK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720361Millipore: Percentage of residual kinase activity of MAP3K9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720281Millipore: Percentage of residual kinase activity of PLK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256605Average Binding Constant for STK17B; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720354Millipore: Percentage of residual kinase activity of MAP2K6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720449Millipore: Percentage of residual kinase activity of PAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256650Average Binding Constant for PIM1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720178Millipore: Percentage of residual kinase activity of GRK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720085Millipore: Percentage of residual kinase activity of CSNK2A1 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720200Millipore: Percentage of residual kinase activity of PRKCH at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720145Millipore: Percentage of residual kinase activity of ERBB4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720304Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720051Millipore: Percentage of residual kinase activity of BRSK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720280Millipore: Percentage of residual kinase activity of PLK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435238Percentage JNK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720411Millipore: Percentage of residual kinase activity of ULK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256571Average Binding Constant for BIKE; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID761522Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced iNOS expression at 10 uM after 24 hrs by Western blot analysis2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Inhibitory effect of resveratrol dimerized derivatives on nitric oxide production in lipopolysaccharide-induced RAW 264.7 cells.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID256667Average Binding Constant for ABL1(E255K); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720205Millipore: Percentage of residual kinase activity of PRKCI at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720372Millipore: Percentage of residual kinase activity of STK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720395Millipore: Percentage of residual kinase activity of TSSK1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435373Percentage PKCzeta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720144Millipore: Percentage of residual kinase activity of EPHB4 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436086Percentage HIPK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435681Percentage MAPKAPK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID256623Average Binding Constant for MYLK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720298Millipore: Percentage of residual kinase activity of CHUK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720182Millipore: Percentage of residual kinase activity of GSK3A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256563Average Binding Constant for ULK3 m; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720319Millipore: Percentage of residual kinase activity of MAPK8 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720139Millipore: Percentage of residual kinase activity of EPHB2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720197Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435315Percentage MARK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID256624Average Binding Constant for FGFR3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720326Millipore: Percentage of residual kinase activity of LIMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720475Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720060Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256660Average Binding Constant for KIT; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID606664Inhibition of human recombinant PKR autophosphorylation using poly[I:C] after 10 mins by luminescent assay2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Identification of new inhibitors of protein kinase R guided by statistical modeling.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID435987Percentage PRK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720165Millipore: Percentage of residual kinase activity of FLT3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720056Millipore: Percentage of residual kinase activity of CDK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256577Average Binding Constant for CLK4; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720038Millipore: Percentage of residual kinase activity of AURKB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720426Millipore: Percentage of residual kinase activity of KIT at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720313Millipore: Percentage of residual kinase activity of ITK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720068Millipore: Percentage of residual kinase activity of CDK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720209Millipore: Percentage of residual kinase activity of PRKD2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435756Percentage Src activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435962Percentage CDK2-cyclinA activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435867Percentage NEK2a activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720437Millipore: Percentage of residual kinase activity of RPS6KB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720208Millipore: Percentage of residual kinase activity of PRKD2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720130Millipore: Percentage of residual kinase activity of EPHA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720114Millipore: Percentage of residual kinase activity of DDR2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720458Millipore: Percentage of residual kinase activity of PDGFRA at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720228Millipore: Percentage of residual kinase activity of PLK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720321Millipore: Percentage of residual kinase activity of MAPK9 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435541Percentage PKA activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720179Millipore: Percentage of residual kinase activity of GRK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720453Millipore: Percentage of residual kinase activity of PAK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256648Average Binding Constant for RPS6KA5 (Kin.Dom 1); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720189Millipore: Percentage of residual kinase activity of HIPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720269Millipore: Percentage of residual kinase activity of SGK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720383Millipore: Percentage of residual kinase activity of MKNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720106Millipore: Percentage of residual kinase activity of CAMK1D at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID586673Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with MEK1 inhibitor PD98059 for 1 hr before compound addition by Western blot analysis2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Involvement of heme oxygenase-1 induction via Nrf2/ARE activation in protection against H2O2-induced PC12 cell death by a metabolite of sesamin contained in sesame seeds.
AID435375Percentage RSK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID674889Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 30 uM relative to control2012Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16
Suppressive effects of coumarins from Mammea siamensis on inducible nitric oxide synthase expression in RAW264.7 cells.
AID256594Average Binding Constant for BMX; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720132Millipore: Percentage of residual kinase activity of EPHA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325697Inhibition of human JNK22007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720316Millipore: Percentage of residual kinase activity of JAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720194Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720409Millipore: Percentage of residual kinase activity of ULK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720140Millipore: Percentage of residual kinase activity of EPHB2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256574Average Binding Constant for STK3_m; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720028Millipore: Percentage of residual kinase activity of NUAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720433Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 202013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720446Millipore: Percentage of residual kinase activity of PAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325698Inhibition of human JNK32007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID597759Inhibition of ALK using FL-Peptide 13, 5-FAM-KKSRGDYMTMQIG-CONH2 substrate at 10 uM after 60 mins by mobility shift assay2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Virtual screening and further development of novel ALK inhibitors.
AID435621Percentage p38alpha MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID256620Average Binding Constant for FLT3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720186Millipore: Percentage of residual kinase activity of HIPK1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720384Millipore: Percentage of residual kinase activity of MUSK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720103Millipore: Percentage of residual kinase activity of CAMK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720025Millipore: Percentage of residual kinase activity of PRKAA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720101Millipore: Percentage of residual kinase activity of CAMK2D at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720329Millipore: Percentage of residual kinase activity of STK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256583Average Binding Constant for CAMKK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720416Millipore: Percentage of residual kinase activity of WNK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720041Millipore: Percentage of residual kinase activity of AXL at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1184501Inhibition of GST-fused full length human TTK compound pre-incubated for 15 mins prior ATP addition by MBP-based assay2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
AID720463Millipore: Percentage of residual kinase activity of PDPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720095Millipore: Percentage of residual kinase activity of CAMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720308Millipore: Percentage of residual kinase activity of IRAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720264Millipore: Percentage of residual kinase activity of MAPK13 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720428Millipore: Percentage of residual kinase activity of SRC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720347Millipore: Percentage of residual kinase activity of MARK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720110Millipore: Percentage of residual kinase activity of DAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID586675Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with JNK inhibitor SP600125 for 1 hr before compound addition by Western blot analysis2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Involvement of heme oxygenase-1 induction via Nrf2/ARE activation in protection against H2O2-induced PC12 cell death by a metabolite of sesamin contained in sesame seeds.
AID720173Millipore: Percentage of residual kinase activity of GCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720033Millipore: Percentage of residual kinase activity of ABL2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435728Percentage JNK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720402Millipore: Percentage of residual kinase activity of NTRK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720278Millipore: Percentage of residual kinase activity of STK33 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256604Average Binding Constant for STK10; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256559Average Binding Constant for EPHB4; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720034Millipore: Percentage of residual kinase activity of ABL2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256613Average Binding Constant for Aurora2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720456Millipore: Percentage of residual kinase activity of PASK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720077Millipore: Percentage of residual kinase activity of CSNK1G1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720234Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435418Percentage PAK5 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720241Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256657Average Binding Constant for LCK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256665Average Binding Constant for ABL1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID747723Inhibition of human DAPK3 at 1 uM2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125).
AID720108Millipore: Percentage of residual kinase activity of DAPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720380Millipore: Percentage of residual kinase activity of MET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720072Millipore: Percentage of residual kinase activity of CDK9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256640Average Binding Constant for PTK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435718Percentage EF2K activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID256668Average Binding Constant for ABL1(H396P); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256578Average Binding Constant for SLK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720439Millipore: Percentage of residual kinase activity of NEK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435300Percentage PAK6 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720290Millipore: Percentage of residual kinase activity of TAOK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720254Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256566Average Binding Constant for TNIK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720483Millipore: Percentage of residual kinase activity of PRKCE at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720385Millipore: Percentage of residual kinase activity of MUSK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435176Percentage PIM2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID256636Average Binding Constant for JNK3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720480Millipore: Percentage of residual kinase activity of PRKCD at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID311015Inhibition of JNK32007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Assessing potency of c-Jun N-terminal kinase 3 (JNK3) inhibitors using 2D molecular descriptors and binary QSAR methodology.
AID720175Millipore: Percentage of residual kinase activity of GRK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720090Millipore: Percentage of residual kinase activity of CLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720392Millipore: Percentage of residual kinase activity of TLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720265Millipore: Percentage of residual kinase activity of MAPK13 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720204Millipore: Percentage of residual kinase activity of PRKCI at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720164Millipore: Percentage of residual kinase activity of FLT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720160Millipore: Percentage of residual kinase activity of FES at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256619Average Binding Constant for RPS6KA3 (Kin.Dom. 1); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720440Millipore: Percentage of residual kinase activity of NEK7 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256672Average Binding Constant for CAMK2G; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256629Average Binding Constant for HCK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256599Average Binding Constant for TTK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720147Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720349Millipore: Percentage of residual kinase activity of MAP2K1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-352013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720328Millipore: Percentage of residual kinase activity of STK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720272Millipore: Percentage of residual kinase activity of SIK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720071Millipore: Percentage of residual kinase activity of CDK9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720193Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720310Millipore: Percentage of residual kinase activity of INSRR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720054Millipore: Percentage of residual kinase activity of BRSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435842Percentage Aurora C activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720159Millipore: Percentage of residual kinase activity of FES at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720089Millipore: Percentage of residual kinase activity of CLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720188Millipore: Percentage of residual kinase activity of HIPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720364Millipore: Percentage of residual kinase activity of CDC42BPB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256659Average Binding Constant for DAPK3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256627Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435669Percentage PDK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720136Millipore: Percentage of residual kinase activity of EPHA8 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720260Millipore: Percentage of residual kinase activity of MAPK11 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720292Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID631280Protection against UVB irradiation-induced cell damage in NHEK assessed as inhibition of PGE2 production at 2 uM pretreated for 24 hrs before UVB irradiation measured after 24 hrs by enzymatic immunoassay2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Sodium dl-α-tocopheryl-6-O-phosphate inhibits PGE₂ production in keratinocytes induced by UVB, IL-1β and peroxidants.
AID256576Average Binding Constant for MKNK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID436076Percentage DYRK1A activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720403Millipore: Percentage of residual kinase activity of NTRK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720346Millipore: Percentage of residual kinase activity of MARK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720334Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720338Millipore: Percentage of residual kinase activity of MAPK3 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720444Millipore: Percentage of residual kinase activity of PAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256573Average Binding Constant for PAK6; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720070Millipore: Percentage of residual kinase activity of CDK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436036Percentage Lck activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720167Millipore: Percentage of residual kinase activity of FLT4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256639Average Binding Constant for PHkg1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720198Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720162Millipore: Percentage of residual kinase activity of FGR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720252Millipore: Percentage of residual kinase activity of RPS6KA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720390Millipore: Percentage of residual kinase activity of NEK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256565Average Binding Constant for MAP4K5; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720080Millipore: Percentage of residual kinase activity of CSNK1G2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720386Millipore: Percentage of residual kinase activity of NEK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720236Millipore: Percentage of residual kinase activity of RIPK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720123Millipore: Percentage of residual kinase activity of EPHA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256631Average Binding Constant for FLT4; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256661Average Binding Constant for PDGFRB; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720155Millipore: Percentage of residual kinase activity of FGFR4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720237Millipore: Percentage of residual kinase activity of RIPK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720447Millipore: Percentage of residual kinase activity of PAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435225Percentage DYRK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID256616Average Binding Constant for CDK5; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720073Millipore: Percentage of residual kinase activity of CHEK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256587Average Binding Constant for ACK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720232Millipore: Percentage of residual kinase activity of PRKX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720246Millipore: Percentage of residual kinase activity of ROS1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720044Millipore: Percentage of residual kinase activity of PTK6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720247Millipore: Percentage of residual kinase activity of ROS1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256612Average Binding Constant for GAK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720414Millipore: Percentage of residual kinase activity of WNK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435847Percentage DYRK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID389516Inhibition of JAK32008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Virtual screening to successfully identify novel janus kinase 3 inhibitors: a sequential focused screening approach.
AID720397Millipore: Percentage of residual kinase activity of TSSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256570Average Binding Constant for PIM2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720223Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720396Millipore: Percentage of residual kinase activity of TSSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720053Millipore: Percentage of residual kinase activity of BRSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720357Millipore: Percentage of residual kinase activity of MAP2K7 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720333Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720151Millipore: Percentage of residual kinase activity of FGFR2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720379Millipore: Percentage of residual kinase activity of MERTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256584Average Binding Constant for CAMK1D; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256590Average Binding Constant for EPHB1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720055Millipore: Percentage of residual kinase activity of CDK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256589Average Binding Constant for EPHA4; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720296Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720331Millipore: Percentage of residual kinase activity of STK10 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256653Average Binding Constant for FGFR1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720172Millipore: Percentage of residual kinase activity of FYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256677Average Binding Constant for STK38L; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435881Percentage ROCK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720240Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720169Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720382Millipore: Percentage of residual kinase activity of MKNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720243Millipore: Percentage of residual kinase activity of RET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720177Millipore: Percentage of residual kinase activity of GRK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID747734Inhibition of human AURKB at 1 uM relative to control2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125).
AID720467Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256649Average Binding Constant for CSK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID720432Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 202013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720122Millipore: Percentage of residual kinase activity of EGFR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720024Millipore: Percentage of residual kinase activity of PRKAA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325696Inhibition of human JNK12007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720450Millipore: Percentage of residual kinase activity of PAK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720369Millipore: Percentage of residual kinase activity of RPS6KA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435339Percentage CaMKKbeta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720253Millipore: Percentage of residual kinase activity of RPS6KA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720137Millipore: Percentage of residual kinase activity of EPHB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720079Millipore: Percentage of residual kinase activity of CSNK1G2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435228Percentage ERK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720031Millipore: Percentage of residual kinase activity of ABL1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720355Millipore: Percentage of residual kinase activity of MAP2K6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720419Millipore: Percentage of residual kinase activity of YES1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720330Millipore: Percentage of residual kinase activity of STK10 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720115Millipore: Percentage of residual kinase activity of DMPK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720462Millipore: Percentage of residual kinase activity of PDPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720112Millipore: Percentage of residual kinase activity of DCLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720266Millipore: Percentage of residual kinase activity of SGK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435378Percentage S6K1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID674890Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production relative to control2012Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16
Suppressive effects of coumarins from Mammea siamensis on inducible nitric oxide synthase expression in RAW264.7 cells.
AID720406Millipore: Percentage of residual kinase activity of TXK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720276Millipore: Percentage of residual kinase activity of SRPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256652Average Binding Constant for CAMK2B; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720322Millipore: Percentage of residual kinase activity of MAPK10 at 1uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256611Average Binding Constant for RIPK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435819Percentage PKBbeta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720058Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720066Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720218Millipore: Percentage of residual kinase activity of FRK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720476Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720351Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720050Millipore: Percentage of residual kinase activity of BMX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720154Millipore: Percentage of residual kinase activity of FGFR3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720035Millipore: Percentage of residual kinase activity of AURKA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720134Millipore: Percentage of residual kinase activity of EPHA7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435704Percentage Aurora B activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720029Millipore: Percentage of residual kinase activity of MAP3K5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID720431Millipore: Percentage of residual kinase activity of EEF2K at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720176Millipore: Percentage of residual kinase activity of GRK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720387Millipore: Percentage of residual kinase activity of NEK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720018Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720455Millipore: Percentage of residual kinase activity of MARK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720239Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720141Millipore: Percentage of residual kinase activity of EPHB3 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435820Percentage PKCalpha activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720366Millipore: Percentage of residual kinase activity of RPS6KA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435613Percentage MNK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720261Millipore: Percentage of residual kinase activity of MAPK11 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720168Millipore: Percentage of residual kinase activity of FLT4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256634Average Binding Constant for CSNK1G2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435250Percentage MSK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720043Millipore: Percentage of residual kinase activity of PTK6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID747744Inhibition of MPS1 (unknown origin)2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125).
AID720294Millipore: Percentage of residual kinase activity of TGFBR1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256614Average Binding Constant for YES; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720143Millipore: Percentage of residual kinase activity of EPHB4 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720242Millipore: Percentage of residual kinase activity of RET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720307Millipore: Percentage of residual kinase activity of IRAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720245Millipore: Percentage of residual kinase activity of MST1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720149Millipore: Percentage of residual kinase activity of FGFR1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720356Millipore: Percentage of residual kinase activity of MAP2K7 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720436Millipore: Percentage of residual kinase activity of RPS6KB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435427Percentage PKBalpha activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720373Millipore: Percentage of residual kinase activity of STK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720083Millipore: Percentage of residual kinase activity of CSNK1D at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720026Millipore: Percentage of residual kinase activity of PRKAA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720206Millipore: Percentage of residual kinase activity of PRKD1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720424Millipore: Percentage of residual kinase activity of RAF1 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID617673Inhibition of JNK1 using ATF2 substrate by TR-FRET assay2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor.
AID720341Millipore: Percentage of residual kinase activity of MAPK1 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720273Millipore: Percentage of residual kinase activity of SIK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720076Millipore: Percentage of residual kinase activity of CHEK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256586Average Binding Constant for STK4; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256561Average Binding Constant for BTK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720036Millipore: Percentage of residual kinase activity of AURKA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720286Millipore: Percentage of residual kinase activity of TAOK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1171175Inhibition of RANKL-induced c-FOS protein expression in ICR mouse BMMC at 1 to 20 uM incubated for 12 hrs by Western blotting method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.
AID720062Millipore: Percentage of residual kinase activity of CDK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720363Millipore: Percentage of residual kinase activity of CDC42BPA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720315Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720171Millipore: Percentage of residual kinase activity of FYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID761533Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 10 uM treated 2 hrs before LPS challenge measured after 24 hrs2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Inhibitory effect of resveratrol dimerized derivatives on nitric oxide production in lipopolysaccharide-induced RAW 264.7 cells.
AID720267Millipore: Percentage of residual kinase activity of SGK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256569Average Binding Constant for PAK7/PAK5; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720275Millipore: Percentage of residual kinase activity of SRPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720166Millipore: Percentage of residual kinase activity of FLT3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720202Millipore: Percentage of residual kinase activity of PRKCQ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720311Millipore: Percentage of residual kinase activity of INSRR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720052Millipore: Percentage of residual kinase activity of BRSK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720156Millipore: Percentage of residual kinase activity of FGFR4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720466Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256596Average Binding Constant for CLK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256626Average Binding Constant for NTRK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256609Average Binding Constant for AAK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256628Average Binding Constant for LYN; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID747725Inhibition of human CLK2 at 1 uM2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125).
AID435256Percentage p38-gamma MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720479Millipore: Percentage of residual kinase activity of PRKCG at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720201Millipore: Percentage of residual kinase activity of PRKCH at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720233Millipore: Percentage of residual kinase activity of PRKX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720203Millipore: Percentage of residual kinase activity of PRKCQ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720191Millipore: Percentage of residual kinase activity of GSG2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720183Millipore: Percentage of residual kinase activity of GSK3B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720227Millipore: Percentage of residual kinase activity of PIM3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720340Millipore: Percentage of residual kinase activity of MAPK1 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256582Average Binding Constant for NEK9; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720119Millipore: Percentage of residual kinase activity of DYRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325699Selectivity for JNK to ERK12007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720279Millipore: Percentage of residual kinase activity of STK33 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720187Millipore: Percentage of residual kinase activity of HIPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720375Millipore: Percentage of residual kinase activity of STK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435706Percentage BRSK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720128Millipore: Percentage of residual kinase activity of EPHA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256674Average Binding Constant for PKMYT1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720207Millipore: Percentage of residual kinase activity of PRKD1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720214Millipore: Percentage of residual kinase activity of MAPKAPK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720109Millipore: Percentage of residual kinase activity of DAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720138Millipore: Percentage of residual kinase activity of EPHB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435493Percentage PKD1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720064Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720365Millipore: Percentage of residual kinase activity of CDC42BPB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720358Millipore: Percentage of residual kinase activity of MYLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720335Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720461Millipore: Percentage of residual kinase activity of PDGFRB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720342Millipore: Percentage of residual kinase activity of MAPKAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720457Millipore: Percentage of residual kinase activity of PASK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256675Average Binding Constant for PTK6; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720211Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720438Millipore: Percentage of residual kinase activity of NEK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720199Millipore: Percentage of residual kinase activity of PRKCZ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720291Millipore: Percentage of residual kinase activity of TAOK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720323Millipore: Percentage of residual kinase activity of MAPK10 at 10uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720022Millipore: Percentage of residual kinase activity of ACVR1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720454Millipore: Percentage of residual kinase activity of MARK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256564Average Binding Constant for MAP3K4; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID747722Inhibition of human PHKG2 at 1 uM2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125).
AID720300Millipore: Percentage of residual kinase activity of IKBKB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720415Millipore: Percentage of residual kinase activity of WNK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720081Millipore: Percentage of residual kinase activity of CSNK1G3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720158Millipore: Percentage of residual kinase activity of FER at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720225Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720443Millipore: Percentage of residual kinase activity of NLK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435979Percentage MST2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720161Millipore: Percentage of residual kinase activity of FGR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435747Percentage PRAK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720473Millipore: Percentage of residual kinase activity of PRKCA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID720180Millipore: Percentage of residual kinase activity of GRK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720046Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720213Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720195Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256642Average Binding Constant for VEGFR2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720231Millipore: Percentage of residual kinase activity of PLK3 at 10uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435854Percentage IKK-beta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720381Millipore: Percentage of residual kinase activity of MET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID740244Neuroprotective activity in human SH-SY5Y cells assessed as reduction of anisomycin-induced cell death at 10 uM incubated for 1 hr prior to anisomycin induction measured after 30 mins by light microscopic analysis2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects.
AID720418Millipore: Percentage of residual kinase activity of YES1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256673Average Binding Constant for PAK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720412Millipore: Percentage of residual kinase activity of VRK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435417Percentage PAK4 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID256664Average Binding Constant for EGFR; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435461Percentage CK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID256647Average Binding Constant for SYK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256581Average Binding Constant for CAMK1G; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720074Millipore: Percentage of residual kinase activity of CHEK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256625Average Binding Constant for PAK3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720374Millipore: Percentage of residual kinase activity of STK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720212Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435723Percentage GSK3-beta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720032Millipore: Percentage of residual kinase activity of ABL1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720344Millipore: Percentage of residual kinase activity of MAPKAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435454Percentage CaMKKalpha activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720057Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720262Millipore: Percentage of residual kinase activity of MAPK12 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435501Percentage SmMLCK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID256645Average Binding Constant for JAK2 (Kin.Dom. 2); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720469Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256608Average Binding Constant for MARK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720192Millipore: Percentage of residual kinase activity of GSG2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720098Millipore: Percentage of residual kinase activity of CAMK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720084Millipore: Percentage of residual kinase activity of CSNK1D at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720417Millipore: Percentage of residual kinase activity of WNK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720303Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720445Millipore: Percentage of residual kinase activity of PAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256630Average Binding Constant for FYN; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256654Average Binding Constant for FGFR2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720258Millipore: Percentage of residual kinase activity of MAPK14 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720019Millipore: Percentage of residual kinase activity of ALK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720120Millipore: Percentage of residual kinase activity of DYRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720299Millipore: Percentage of residual kinase activity of CHUK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720100Millipore: Percentage of residual kinase activity of CAMK2G at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256670Average Binding Constant for ABL1(T315I); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID381433Effect on U50488-induced analgesic activity in C57BL/6 mouse assessed as tail withdrawal latency at 10 mg/kg, ip2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.
AID720078Millipore: Percentage of residual kinase activity of CSNK1G1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256607Average Binding Constant for STK18; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720389Millipore: Percentage of residual kinase activity of NEK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256671Average Binding Constant for ABL1(Y253F); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720420Millipore: Percentage of residual kinase activity of ZAP70 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720343Millipore: Percentage of residual kinase activity of MAPKAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720039Millipore: Percentage of residual kinase activity of AURKC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256615Average Binding Constant for p38-gamma; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720017Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435374Percentage PLK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720215Millipore: Percentage of residual kinase activity of MAPKAPK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720190Millipore: Percentage of residual kinase activity of HIPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256618Average Binding Constant for PHkg2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720423Millipore: Percentage of residual kinase activity of DAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720255Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720407Millipore: Percentage of residual kinase activity of TXK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720309Millipore: Percentage of residual kinase activity of IRAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720104Millipore: Percentage of residual kinase activity of CAMK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720345Millipore: Percentage of residual kinase activity of MAPKAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256655Average Binding Constant for CSNK1G1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720042Millipore: Percentage of residual kinase activity of AXL at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720251Millipore: Percentage of residual kinase activity of RPS6KA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720113Millipore: Percentage of residual kinase activity of DDR2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256638Average Binding Constant for PRKAA1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720063Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720121Millipore: Percentage of residual kinase activity of EGFR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720481Millipore: Percentage of residual kinase activity of PRKCD at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256643Average Binding Constant for CAMK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720217Millipore: Percentage of residual kinase activity of PKN2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID435223Percentage CSK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720371Millipore: Percentage of residual kinase activity of SRPK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256622Average Binding Constant for JNK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720274Millipore: Percentage of residual kinase activity of SRPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720353Millipore: Percentage of residual kinase activity of MINK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720148Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256588Average Binding Constant for PCTK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720065Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720399Millipore: Percentage of residual kinase activity of TEC at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720359Millipore: Percentage of residual kinase activity of MYLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720222Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436083Percentage ERK8 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720472Millipore: Percentage of residual kinase activity of PRKCA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256669Average Binding Constant for ABL1(M351T); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720484Millipore: Percentage of residual kinase activity of PRKCZ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720295Millipore: Percentage of residual kinase activity of TGFBR1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720221Millipore: Percentage of residual kinase activity of PHKG2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720257Millipore: Percentage of residual kinase activity of RPS6KA6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1171174Inhibition of RANKL-stimulated JNK in ICR mouse BMMC assessed as reduction in c-Jun phosphorylation at 1 to 20 uM incubated for 12 hrs by Western blotting method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.
AID720339Millipore: Percentage of residual kinase activity of MAPK3 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720378Millipore: Percentage of residual kinase activity of MERTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256575Average Binding Constant for NEK6; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720157Millipore: Percentage of residual kinase activity of FER at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720270Millipore: Percentage of residual kinase activity of SGK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720092Millipore: Percentage of residual kinase activity of CLK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720224Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720421Millipore: Percentage of residual kinase activity of ZAP70 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID747724Inhibition of human STK3 at 1 uM2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125).
AID720348Millipore: Percentage of residual kinase activity of MAP2K1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-352013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256666Average Binding Constant for ABL1(Q252H); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720268Millipore: Percentage of residual kinase activity of SGK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720219Millipore: Percentage of residual kinase activity of FRK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID740242Inhibition of JNK3 in human PBMCs assessed as decrease in LPS-induced TNFalpha mRNA level after 4 hrs by real-time reverse transcription-PCR analysis2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects.
AID720320Millipore: Percentage of residual kinase activity of MAPK9 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720061Millipore: Percentage of residual kinase activity of CDK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435370Percentage p38beta MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720301Millipore: Percentage of residual kinase activity of IKBKB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720129Millipore: Percentage of residual kinase activity of EPHA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720297Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256646Average Binding Constant for JAK1 (Kin.Dom. 1); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720185Millipore: Percentage of residual kinase activity of HIPK1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID720435Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP122013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720408Millipore: Percentage of residual kinase activity of ULK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256676Average Binding Constant for SRC; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256656Average Binding Constant for p38-alpha; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256591Average Binding Constant for EPHA5; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1171176Inhibition of RANKL-induced NFATc1 protein expression in ICR mouse BMMC at 1 to 20 uM incubated for 12 hrs by Western blotting method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.
AID720091Millipore: Percentage of residual kinase activity of CLK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720302Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720226Millipore: Percentage of residual kinase activity of PIM3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720049Millipore: Percentage of residual kinase activity of BMX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256595Average Binding Constant for CLK3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435123Percentage NEK7 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720067Millipore: Percentage of residual kinase activity of CDK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720125Millipore: Percentage of residual kinase activity of EPHA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720362Millipore: Percentage of residual kinase activity of CDC42BPA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720045Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435363Percentage MELK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435233Percentage HIPK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720305Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720047Millipore: Percentage of residual kinase activity of BLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720285Millipore: Percentage of residual kinase activity of MAP3K7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720400Millipore: Percentage of residual kinase activity of TEK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256560Average Binding Constant for FGR; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256579Average Binding Constant for MAP3K5; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256610Average Binding Constant for Aurora3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435215Percentage AMPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435731Percentage MNK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720229Millipore: Percentage of residual kinase activity of PLK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720127Millipore: Percentage of residual kinase activity of EPHA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720174Millipore: Percentage of residual kinase activity of GCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720317Millipore: Percentage of residual kinase activity of JAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720393Millipore: Percentage of residual kinase activity of TLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436071Percentage CHK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID256600Average Binding Constant for EPHA8; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720094Millipore: Percentage of residual kinase activity of CSK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720464Millipore: Percentage of residual kinase activity of PRKACA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720235Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720452Millipore: Percentage of residual kinase activity of PAK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256621Average Binding Constant for CAMK2A; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720082Millipore: Percentage of residual kinase activity of CSNK1G3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720391Millipore: Percentage of residual kinase activity of NEK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720153Millipore: Percentage of residual kinase activity of FGFR3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720482Millipore: Percentage of residual kinase activity of PRKCE at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720248Millipore: Percentage of residual kinase activity of TYRO3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720448Millipore: Percentage of residual kinase activity of PAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256585Average Binding Constant for EPHA7; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256641Average Binding Constant for ABL2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256601Average Binding Constant for EPHA3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720210Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435865Percentage MKK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720360Millipore: Percentage of residual kinase activity of MAP3K9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256632Average Binding Constant for CDK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256658Average Binding Constant for p38-beta; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435260Percentage RSK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435317Percentage PIM1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435814Percentage PIM3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720293Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720096Millipore: Percentage of residual kinase activity of CAMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256635Average Binding Constant for CAMK2D; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720021Millipore: Percentage of residual kinase activity of ACVR1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720332Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720131Millipore: Percentage of residual kinase activity of EPHA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720196Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256580Average Binding Constant for CAMKK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256644Average Binding Constant for CSNK1E; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720086Millipore: Percentage of residual kinase activity of CSNK2A1 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720327Millipore: Percentage of residual kinase activity of LIMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720216Millipore: Percentage of residual kinase activity of PKN2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720336Millipore: Percentage of residual kinase activity of LYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720093Millipore: Percentage of residual kinase activity of CSK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID586674Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with MEK2 inhibitor U0126 for 1 hr before compound addition by Western blot analysis2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Involvement of heme oxygenase-1 induction via Nrf2/ARE activation in protection against H2O2-induced PC12 cell death by a metabolite of sesamin contained in sesame seeds.
AID256663Average Binding Constant for INSR; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720306Millipore: Percentage of residual kinase activity of IRAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256567Average Binding Constant for EPHA6; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720097Millipore: Percentage of residual kinase activity of CAMK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720150Millipore: Percentage of residual kinase activity of FGFR1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256651Average Binding Constant for DAPK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720430Millipore: Percentage of residual kinase activity of EEF2K at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720425Millipore: Percentage of residual kinase activity of RAF1 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720352Millipore: Percentage of residual kinase activity of MINK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256572Average Binding Constant for STK36; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720259Millipore: Percentage of residual kinase activity of MAPK14 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720283Millipore: Percentage of residual kinase activity of SYK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1189540Inhibition of JNK1 (unknown origin) by time-resolved fluorescence assay2015Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1
Inhibitors of c-Jun N-terminal kinases: an update.
AID720478Millipore: Percentage of residual kinase activity of PRKCG at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID473197Inhibition of JNK32010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Small molecule JNK (c-Jun N-terminal kinase) inhibitors.
AID720238Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720105Millipore: Percentage of residual kinase activity of CAMK1D at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720146Millipore: Percentage of residual kinase activity of ERBB4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720048Millipore: Percentage of residual kinase activity of BLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720250Millipore: Percentage of residual kinase activity of RPS6KA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720441Millipore: Percentage of residual kinase activity of NEK7 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256637Average Binding Constant for JNK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720394Millipore: Percentage of residual kinase activity of TSSK1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720422Millipore: Percentage of residual kinase activity of DAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID761521Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IL-1beta release at 10 uM after 24 hrs by ELISA2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Inhibitory effect of resveratrol dimerized derivatives on nitric oxide production in lipopolysaccharide-induced RAW 264.7 cells.
AID720256Millipore: Percentage of residual kinase activity of RPS6KA6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720459Millipore: Percentage of residual kinase activity of PDGFRA at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720118Millipore: Percentage of residual kinase activity of STK17A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720401Millipore: Percentage of residual kinase activity of TEK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256662Average Binding Constant for ERBB2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720099Millipore: Percentage of residual kinase activity of CAMK2G at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435338Percentage CaMK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720027Millipore: Percentage of residual kinase activity of NUAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720370Millipore: Percentage of residual kinase activity of SRPK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720367Millipore: Percentage of residual kinase activity of RPS6KA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720376Millipore: Percentage of residual kinase activity of STK24 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID319311Inhibition of human JNK1 by radiometric assay2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (1).
AID720474Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID747721Inhibition of human PIM2 at 1 uM2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125).
AID720312Millipore: Percentage of residual kinase activity of ITK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720314Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720117Millipore: Percentage of residual kinase activity of STK17A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720170Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720277Millipore: Percentage of residual kinase activity of SRPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1171177Inhibition of RANKL/M-CSF-stimulated osteoclastogenesis in ICR mouse BMMC assessed as reduction in TRAP positive multinucleated cells at 1 to 20 uM incubated for 7 days by light microscopy2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.
AID617672Displacement of biotin-RPKRPTTLNLF from GST tagged JNK1 using ATF2 substrate by dissociation enhanced lanthanide fluoro-immuno assay2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor.
AID256568Average Binding Constant for STK17A; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256617Average Binding Constant for TEK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID493040Navigating the Kinome2011Nature chemical biology, Apr, Volume: 7, Issue:4
Navigating the kinome.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1797457Homogeneous Time-Resolved Fluorescence (HTRF) Enzyme Assay from Article 10.1016/S1074-5521(03)00159-5: \\The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity.\\2003Chemistry & biology, Aug, Volume: 10, Issue:8
The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity.
AID1799705JNK Kinase Assay from Article 10.1016/j.chembiol.2011.11.010: \\Discovery of potent and selective covalent inhibitors of JNK.\\2012Chemistry & biology, Jan-27, Volume: 19, Issue:1
Discovery of potent and selective covalent inhibitors of JNK.
AID1801919Kinase Assay from Article 10.1021/acschembio.5b00940: \\Structural and Functional Analysis of the Allosteric Inhibition of IRE1a with ATP-Competitive Ligands.\\2016ACS chemical biology, 08-19, Volume: 11, Issue:8
Structural and Functional Analysis of the Allosteric Inhibition of IRE1α with ATP-Competitive Ligands.
AID1798646JAK3 Inhibition Assay from Article 10.1021/jm800662z: \\Virtual screening to successfully identify novel janus kinase 3 inhibitors: a sequential focused screening approach.\\2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Virtual screening to successfully identify novel janus kinase 3 inhibitors: a sequential focused screening approach.
AID1345333Human mitogen-activated protein kinase 8 (JNK subfamily)2001Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 98, Issue:24
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.
AID1345355Human mitogen-activated protein kinase 9 (JNK subfamily)2001Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 98, Issue:24
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.
AID1345347Human mitogen-activated protein kinase 10 (JNK subfamily)2001Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 98, Issue:24
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1802072Isothermal titration calorimetry from Article 10.1016/j.chembiol.2016.06.017: \\Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase.\\2016Cell chemical biology, Oct-20, Volume: 23, Issue:10
Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2003Chemistry & biology, Aug, Volume: 10, Issue:8
The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity.
AID1811Experimentally measured binding affinity data derived from PDB2003Chemistry & biology, Aug, Volume: 10, Issue:8
The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,463)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's606 (41.42)29.6817
2010's765 (52.29)24.3611
2020's92 (6.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 7.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index7.23 (24.57)
Research Supply Index7.30 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (7.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.13%)5.53%
Reviews10 (0.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other1,472 (99.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]